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ABSTRACT 
 Brain metastases of human epidermal growth factor receptor 2 (HER2)-positive 
breast cancer are presenting an increasing problem in the clinic. While HER2-targeted 
therapies effectively control systemic disease, their efficacy against brain metastases is 
hindered by their inability to penetrate the blood-brain and blood-tumor barriers (BBB and 
BTB). One promising strategy to increase brain penetration of systemic therapeutics is to 
exploit endogenous transport systems at the BBB to shuttle drugs into the brain. Previous 
studies showed that gold nanoparticles designed to shed transferrin receptor (TfR)-
targeting ligands under acidic conditions encountered during transcytosis of the BBB 
demonstrated increased accumulation in the brain. The focus of this work was to determine 
whether therapeutic, TfR-targeted nanoparticles using an improved acid-cleavable 
chemistry could be used to deliver therapeutically useful amounts of drug to the brain.  
 To accomplish this goal, a new animal model of HER2-positive breast cancer brain 
metastasis was developed in an attempt to create a clinically representative, impermeable 
barrier to standard therapeutics. This new model establishes brain metastases by methods 
that more closely resemble the human disease, forming whole-body tumors that eventually 
metastasize to the brain. Brain metastases formed by this new methodology show no 
response to standard HER2-targeted agents, mimicking the clinical situation. 
 Next, efficacy and brain uptake of TfR-targeted, single-agent therapeutic 
nanoparticles were investigated in the newly developed model, as well as two common 
models from the literature. These nanoparticles show significant tumor growth delay and 
increased accumulation in both brain metastases and healthy brain tissue in all three 
models, highlighting their therapeutic potential. Additionally, non-BBB-penetrant small 
 vii 
molecule and non-targeted nanoparticle therapeutics elicit a substantial antitumor response 
as well as brain tumor accumulation in the most commonly used literature model. In 
contrast, the new model and one gaining popularity in the literature provide for a more 
clinically relevant, impermeable barrier to non-BBB-penetrant agents, indicating that the 
method used to establish brain metastases can affect efficacy and brain uptake of 
therapeutics. 
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Chapter I 
INTRODUCTION 
1.1 Recent developments in cancer treatment: opportunities and challenges  
Significant improvements in cancer care have been made over the past decade, as 
evidenced by declining incidence and mortality rates. Overall cancer incidence, defined as 
the rate of cancer diagnoses per 100,000 residents, decreased significantly, dropping a near 
1% annually (1). For some cancer types, such as prostate, lung, colorectal and stomach 
cancers, incidence has dropped at even faster rates (Fig 1.1A). A number of factors have 
contributed to this decline, particularly prevention efforts (e.g. routine primary care, 
tobacco cessation, programs that target obesity) and advances in screening practices (1,2). 
Additionally, because of improvements in early detection and treatment, more Americans 
are surviving cancer, with about two-thirds of Americans diagnosed with cancer today 
living for at least 5 years (3,4). Since its peak in the early 1990s, overall cancer mortality 
has dropped steadily, translating into an estimated 2 million fewer deaths (2,5). For the 
most common cancer types – lung, breast, prostate, and colorectal – mortality rates have 
decreased significantly, with an annual rate of decline of 2% (Fig 1.1B). 
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Fig. 1.1. Declining cancer incidence and mortality rates in the US. Trends in Surveillance, 
Epidemiology, and End Results (SEER) incidence (A) and cancer death rates (B) for 
common cancers, 2004 to 2013. * = P < 0.05. Data from (6).  
Most importantly, recent advances in cancer research and treatment have led to 
more durable therapeutic responses and improvement in long-term survival. Perhaps the 
importance of continued investment in new drugs and therapeutic strategies is best 
illustrated by recent developments in the treatment of metastatic melanoma using immune 
checkpoint inhibitors. In a long-term follow-up of a phase I study of nivolumab 
monotherapy, a programmed death 1 (PD-1) inhibitor, in metastatic melanoma patients, 
more than one third of patients were alive after 5 years, a significantly higher proportion 
than observed previously (7). Similarly, the 3-year survival for patients in a phase I study 
with advanced melanoma treated with another PD-1 inhibitor, pembrolizumab, was 40% 
(8). Additionally, a recent phase III clinical trial showed that, for high-risk patients with 
metastatic melanoma, treatment with the cytotoxic T-lymphocyte–associated antigen 4 
(CTLA-4) inhibitor ipilimumab led to significantly higher rates of recurrence-free survival, 
  
3 
overall survival, and distant metastasis–free survival after 5 years than previously observed 
(9). The results from these as well as other recent clinical trials demonstrate the meaningful 
clinical benefit that can be achieved by sustained investment in cancer research, 
particularly the investigation of new anti-cancer therapeutic approaches. 
1.1.1 Brain metastases as emerging threats to long-term survival 
Brain metastases are becoming increasingly more common among cancer survivors 
as more effective treatments prolong survival, thus giving the cancer more time to spread 
to the brain. Metastatic brain tumors most commonly arise from lung, skin (melanoma) and 
breast cancers, but have also been observed in patients with other cancer types (10). The 
incidence of metastasis to the brain is highest in patients with lung cancer. Brain metastases 
are present in approximately 10-25% of these patients at initial diagnosis, with another 40-
50% developing them over time and an even greater incidence at autopsy (11). For non-
small cell lung cancer (NSCLC) patients in particular, brain metastases are extremely 
common and confer a generally poor prognosis (12). In patients with metastatic melanoma, 
autopsy reports indicate the incidence of brain metastasis may be as high as 75% (13). 
Similar to lung cancer patients, the prognosis for patients with brain metastases resulting 
from melanoma is dismal, with a median survival of approximately 4 months after 
diagnosis (14). For patients with breast cancer, brain metastasis incidence varies with the 
cancer subtype. Patients with triple-negative or human epidermal growth factor receptor 2 
(HER2)-positive breast cancers have a brain metastasis incidence of approximately 20% 
and 25-50%, respectively (15-17). Of particular concern, for HER2-positive, metastatic 
breast cancer patients, the brain is increasingly the first site of progression after treatment 
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(18). The incidence is lower in patients with estrogen receptor (ER) positive disease 
(15,16).  
Detection of brain metastases is critical for initial staging of patients with metastatic 
disease. In some cases, brain metastases are indicated by neurological symptoms. However, 
brain metastases are asymptomatic 60-75% of the time (19). Symptoms of brain metastases 
typically vary depending on their size, number and location. Persistent headache is the most 
common presenting symptom, but patients may also present with more serious symptoms 
such as seizures, cognitive decline and loss of motor and sensory function as a consequence 
of increased intracranial pressure (20). In symptomatic or high-risk patients with known 
malignancies, computed tomography (CT) or magnetic resonance imaging (MRI) 
modalities are typically used to detect brain metastases (21).  
Current treatments for brain metastases are largely palliative, as surgery and 
radiation remain the cornerstones of therapy (22). For patients with only one lesion or a 
small number of lesions in accessible regions of the brain, surgery may be a viable option 
and provide initial relief of symptoms. Stereotactic radiosurgery (SRS) or whole-brain 
radiotherapy (WBRT) are the two most common types of radiation therapy used in brain 
metastasis patients. These treatment strategies have been associated with modest initial 
clinical improvement in most patients, but the responses are not durable (23,24). 
Improvements in patient survival are measured in weeks or months. Additionally, despite 
recent advances, such as image-based guidance for surgical resection (25), these treatment 
strategies have several limitations depending on the location of the brain tumor as well as 
significant, well-recognized adverse effects (22). Most importantly, standard 
chemotherapy and molecularly targeted drugs that effectively control systemic disease 
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have demonstrated little to no efficacy against brain metastases in the clinic (26,27). Only 
a handful of clinical responses have been reported, and the effects are modest (28-30). 
Clinical data on the responsiveness of brain metastases to the combination of chemotherapy 
and WBRT are also disappointing (27).  
Historically, the lack of durability in response was not a significant problem 
because most patients developed brain metastases late in the course of their disease and 
systemic progression was typically to blame for mortality. Thus, development of treatment 
strategies for brain metastases was not a priority. However, as new systemic therapies 
continue to extend survival for metastatic cancer patients, brain metastases are expected to 
become more prevalent and arise more often in other cancer types. Unless improvements 
are made in the treatment of these brain metastases, an increasing proportion of patients 
will be at risk of mortality as a result of brain progression, even at a time when their 
systemic disease is well-controlled. 
1.1.2 Human epidermal growth factor 2 (HER2)-positive breast cancer brain 
metastases 
Human epidermal growth factor 2 (HER2)-positive, metastatic breast cancer is a 
particularly compelling example where brain metastases threaten to limit the gains made 
with improved systemic therapies. HER2 overexpression is observed in approximately 
25% of human breast cancers, and is associated with increased aggressiveness of the tumor 
and poor patient prognosis (31). The anti-HER2 monoclonal antibody trastuzumab was 
fast-tracked by the FDA and approved in 1998 as first-line therapy for the treatment of 
metastatic, HER2-positive cancer based on data from a pivotal trial demonstrating that the 
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addition of trastuzumab to chemotherapy improved disease-free and overall survival (32). 
However, shortly after the introduction of trastuzumab, clinicians started to observe an 
apparent increase in the incidence of brain metastases compared to historical numbers. This 
observation led to a number of retrospective studies reporting incidences of approximately 
25-40% (33-37). The findings from these studies are provided in Table 1.1.  
 
Table 1.1. Incidence of brain metastases among patients with HER2-positive breast cancer, 
as documented in retrospective studies. BM, brain metastases. Adapted from (17).  
Since then, considerable clinical data has accumulated on the incidence of brain 
metastases in HER2-positive breast cancer patients and their outcomes. Current estimates 
suggest that up to 50% of metastatic, HER2-positive breast cancer patients will develop 
brain metastases over the course of their disease, and the incidence appears to be rising 
(38). Though systemic disease is well-controlled with trastuzumab and other HER2-
targeted therapies, brain metastases from HER2-positive breast cancer patients do not 
respond to therapy, and are often the reason for treatment failure (36,39). The limited 
efficacy of these agents is mostly attributed to their lack of penetration through the blood-
  
7 
brain and blood-tumor barriers (BBB and BTB), though this is fiercely debated in the 
literature (see sections 1.2.3 and 2.1.2). Nevertheless, one thing is clear: improvements in 
systemic control and overall survival with HER2-targeted therapy have unveiled a patient 
population in whom brain metastases are a significant source of mortality that would have 
otherwise remained silent. 
The changing face of HER2-positive, metastatic disease has broader implications, 
as similar advances in systemic treatment are being made in other cancers. The 
combination of cancer types that have a high propensity to colonize the brain and 
therapeutics that are effective systemically, but that do not penetrate the brain creates the 
opportunity for brain metastatic cancers to become an even greater clinical challenge, 
limiting the gains that have been made over the past decades in controlling systemic 
disease. Additionally, the example of HER2-positive breast cancer brain metastasis 
illustrates factors common to many brain diseases, namely: (i) complex disease progression 
reducing the possibility of a single “silver bullet” treatment, (ii) limited to no disease-
modifying treatment options currently available, and (iii) few promising candidate 
therapies in the pipeline. There is reason to be hopeful, however, as new strategies to 
increase the brain uptake of therapeutics begin to emerge. 
1.2 The blood-brain and blood-tumor barriers (BBB and BTB) 
 1.2.1 Structure and function of the BBB 
A major reason for the limited progress in treating brain diseases is the inability of 
most systemic therapeutics to access the brain from the blood. The delivery of drugs to the 
  
8 
brain is impaired by the blood-brain barrier (BBB), an anatomical barrier that separates the 
vasculature and brain parenchyma. This highly restrictive, physiologic barrier excludes 
more than 98% of small-molecule drugs and nearly all large-molecule therapeutics from 
the brain (40). The BBB problem is illustrated in Figure 1.2, a whole body autoradiogram 
of a mouse sacrificed shortly after systemic administration of a radiolabeled small 
molecule, histamine. Despite the common misconception, most small molecules do not 
readily cross the BBB (see section #). 
 
Fig. 1.2. Radiolabeled histamine accumulates in all organs of an adult mouse, except for 
the brain and spinal cord, following intravenous injection. Image from (40). 
The BBB is formed by endothelial cells, pericytes and astrocyte end foot processes 
(Fig. 1.3), and plays a key role in maintaining homeostasis within the brain, with functions 
including: (i) control of molecular traffic (e.g. influx and efflux of waste), (ii) maintenance 
of optimum ion concentrations for neural signaling and (iii) control of immune surveillance 
(41). These diverse and finely controlled functions are largely facilitated by the presence 
of tight junctions between the endothelial cells, a key feature of the BBB (42). The 
junctions significantly reduce paracellular diffusion of polar solutes, macromolecules and 
cells, forcing solute transport into the brain to primarily occur across individual endothelial 
cells, where it can be tightly controlled. Even sodium ions with a hydrated radius of 3.6 Å 
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cannot squeeze past them. Nearby supporting cells, particularly astrocytes, play a critical 
role in maintaining the tight junctions and barrier function (42).  
 
Fig. 1.3. Schematic of the BBB. Unlike those that line a general blood vessel (A) 
endothelial cells lining a brain blood vessel (B) form tight junctions at their margins, that 
are further modified by pericytes and astrocyte end feet to form the BBB. 
 1.2.2 Solute transport at the BBB: regulation, not isolation 
Though the BBB severely limits the passage of compounds into the brain, its role 
is one of regulation, not isolation. Several transport systems exist at the BBB endothelium 
to allow the influx of necessary nutrients and their carrier proteins. There are six main 
transport mechanisms at the BBB, including: (i) passive paracellular diffusion (PPD), (ii) 
passive transcellular diffusion (PTD), (iii) solute carrier proteins (SCP), (iv) receptor-
mediated transcytosis (RMT), (v) adsorptive-mediated transcytosis (AMT) and (vi) tight 
junction modulation (TJM) (Fig. 1.4) (42). 
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Fig. 1.4. Solute transport systems at the BBB. Solutes can cross the BBB through six 
different pathways: (i) passive paracellular diffusion, (ii) passive transcellular diffusion, 
(iii) solute carrier protein influx, (iv) receptor-mediated transcytosis, (v) adsorptive-
mediated transcytosis and (vi) tight junction modulation. 
 PTD is primarily limited to small (<450 Da), lipophilic molecules capable of 
diffusing through the cell membrane. Molecules with high polar surface areas (>60-80 Å2) 
and that tend to form more than 6 hydrogen bonds, a factor that increases the free energy 
requirement of moving from the aqueous blood to lipid membrane, are severely restricted 
from crossing by PTD (42). Additionally, tight junctions severely inhibit PPD of polar 
solutes. Thus, the polar solutes are generally incapable of passively diffusing through the 
BBB. 
 This restricted diffusion of polar solutes potentially isolates the brain from many 
essential nutrients, such as glucose, amino acids and nucleosides. However, the BBB 
endothelium contains a number of specific transport proteins to supply the brain with these 
substances (42). SCPs on the apical surface of the BBB recognize their solute in the blood 
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and transport it into the BBB endothelial cells by facilitative diffusion. Equivalent transport 
proteins on the basal membrane then transport the solute into the brain parenchyma. SCPs 
are highly specific for their solute and often directional, limiting their ability to transport 
different or new compounds. Facilitative diffusion through SCPs is also restricted to small 
molecules capable of moving through the protein channels. 
 Transcytosis mechanism exist to transport macromolecules such as proteins across 
the BBB. In this process, events on the apical surface of the BBB trigger the formation of 
an endocytic vesicle encapsulating the macromolecules. The vesicle is then routed to the 
basolateral side of the endothelium where it fuses with the basal membrane to release the 
macromolecules into the brain. In RMT, the specific binding of a macromolecular ligand 
to its transcytosing receptor on the apical side of the BBB triggers the internalization. 
Dissociation of the ligand and receptor occurs during the cellular transit or the exocytic 
event. Several serum proteins use this process to enter the brain from circulation, including: 
(i) transferrin (Tf), (ii) insulin and (iii) low-density lipoprotein-receptor-related proteins 1 
and 2 (LRP1 and LRP2) (42). In contrast, AMT is a non-specific process that requires the 
transcytosing protein to be highly cationic. Interaction with the negatively charged proteins 
on the endothelial cell surface induces transcytosis, though the exact mechanisms by which 
AMT occurs are not as well-understood as those for RMT (43). 
 The final mechanism for solute transport at the BBB is TJM. TJM can be induced 
pharmacologically or by cell signaling, and results in complete or partial opening of the 
PPD pathway. TJM mainly occurs in pathological conditions such as malignant gliomas 
(44).  
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 1.2.3 Barrier integrity in HER2-positive breast cancer brain metastases 
 There is considerable debate in the brain metastasis research field regarding the 
extent to which the BBB remains intact with brain metastases in the form of the blood-
tumor barrier (BTB). Imaging studies showing a greater uptake of contrast agents in brain 
metastases compared with healthy tissue have suggested that the lesions may have some 
increased permeability (Fig. 1.5). On the other hand, chemotherapy has been 
unambiguously ineffective in the clinic (10). Although metastatic cancer is generally 
considered incurable, brain metastases appear to be more refractory to standard 
therapeutics than systemic tumors. At least two theories may explain this phenomenon. 
First, metastatic tumor cells in the brain are more resistant to chemotherapy than those in 
systemic metastases either mediated by the brain microenvironment or as a result of their 
late development following multiple rounds of chemotherapy. Second, even if the barrier 
has some increased permeability, it is not sufficiently permeable to allow adequate drug 
accumulation in the brain metastases. To further complicate the debate, there is also 
evidence that suggests BBB/BTB permeability may be cancer type- and even subtype-
dependent (45). 
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Fig. 1.5. Axial MRI images of multiple brain metastases in a HER2-positive breast cancer 
patient. Lesions in the left frontal lobe (A) and left cerebellum (B) show uptake of 
gadolinium contrast agent in T1-weighted scans. Images from (17). 
In the case of HER2-positive breast cancer brain metastases, the available evidence 
suggests that both theories may be at play. Recent studies in experimental brain metastasis 
models indicate that the brain microenvironment has a role in resistance (46). Considerable 
evidence has also accumulated to suggest that HER2-targeted therapeutic efficacy is 
severely diminished by poor brain penetration through a non-permissive BBB/BTB 
(45,47,49,50). In one study, the ratio of trastuzumab levels in the serum to cerebrospinal 
fluid (CSF) was 420:1. Even after WBRT, which is thought to disrupt the BBB, the ratio 
only rose to 76:1 (47). These levels are considered subtherapeutic. However, the CSF 
represents a separate compartment from the brain parenchyma, separated from the brain by 
the glia limitans (48). Perhaps more convincing evidence for inadequate therapeutic 
penetration as a reason for its ineffectiveness comes from an investigation of uptake in 
brain metastases resected from HER2-positive breast cancer patients. Significant 
heterogeneity in lapatinib concentrations was observed both among patients and within 
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individual lesions (49). This theory is further strengthened by a study characterizing the 
incidence and timing of isolated brain metastases in patients with HER2-positive, 
metastatic breast cancer treated with trastuzumab as first-line treatment. Approximately 
10% of patients developed isolated brain metastases as first site of tumor progression, with 
brain progression occurring at a time when their systemic disease was responsive to 
trastuzumab (50). These data support the hypothesis that the brain is a “sanctuary site”, as 
the BBB/BTB limit the ability of drugs to achieve sufficient accumulation in brain 
metastases to elicit an antitumor response. Thus, new strategies to overcome impaired drug 
delivery to brain metastases are essential to improve clinical outcomes, particularly for 
HER2-positive, metastatic breast cancer patients.  
1.3 Current approaches for drug delivery to the brain 
1.3.1 Physically bypassing the BBB 
Drug delivery methods that physically bypass the BBB have been investigated for 
several decades to treat brain diseases. Three similar approaches involving direct 
introduction of drug to the brain parenchyma have been developed with varying, but overall 
limited success, namely: (i) intracerebral implantation (ICI), (ii) intracerebroventricular 
(ICV) or intraventricular infusion and (iii) convection-enhanced diffusion or delivery 
(CED) (40). 
ICI involves direct implantation of drugs into the brain parenchyma. This method 
was piloted in glioma patients by crudely placing a chemotherapeutic-soaked sponge in the 
tumor-resection cavity to provide immediate chemotherapy to residual tumor cells (51,52). 
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Following the introduction of biodegradable polymers to medicine in the 1980s, several 
drug-loaded, biodegradable wafers have been investigated using the same, but more-
refined approach, particularly for gliomas (53,54). Similarly, ICV infusion involves direct 
intraventricular delivery of drugs to the CSF, allowing the drug to access the entire 
ventricular system. This approach has been moderately successful in cases where the 
disease target is in the subarachnoid space (55). However, both the ICI and ICV methods 
have demonstrated little to no clinical benefit over systemic treatments for most brain 
diseases, largely due to limited drug penetration from the site of introduction. Because 
these delivery methods are diffusion-mediated, drug concentration drops off exponentially 
with the distance from the implantation site (40).  
CED attempts to improve upon the diffusional limitations of ICI and ICV. Unlike 
diffusion-limited delivery, CED provides pressure-driven bulk flow of drug into the brain 
parenchyma to enhance its interstitial penetration. The bulk flow is created by a small 
pressure gradient from an infusion pump that pushes the drug through a catheter targeted 
within the brain. Initial clinical investigation suggested that CED may hold some promise, 
effectively delivering therapeutics to substantial volumes of tissue (56). However, several 
technical limitations, such as the catheter design, infusate reflux and post-procedural 
imaging, have limited its reliability. Two CED treatments have reached phase III clinical 
trials in glioblastoma multiforme (GBM) patients, but ultimately failed owing in large part 
to these technical shortcomings (57). Research on CED delivery is ongoing to address these 
limitations.  
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1.3.2 Transiently disrupting the BBB 
Methods to temporarily disrupt the BBB have also been investigated to enable brain 
delivery of circulating drugs. One such technique involves arterial injection of a 
hyperosmotic solution such as mannitol. The high salt concentration in the blood causes 
shrinkage of endothelial cells at the BBB endothelium and consequently stretching of tight 
junctions (58,59). Expansion of the tight junctions increases the permeability of the 
paracellular pathway, allowing circulating drugs to enter the brain. This procedure has been 
shown to improve delivery of therapeutics to brain tumors, and has been used most 
successfully for primary central nervous system lymphoma (60,61). Other agents such as 
bradykinin analogs have also been investigated (62). While this technique may be an 
effective means to deliver drugs to large brain regions, it is an invasive procedure that 
brings significant side effects, including seizures and hypotension (63). These effects are 
likely due to accumulation of serum proteins and toxic substances in the brain following 
widespread, non-specific disruption. Additionally, in the case of metastatic cancers, there 
is concern that BBB disruption may allow circulating cancer cells to more readily access 
the brain, potentially forming new brain lesions. 
Recently, the use of focused ultrasound (FUS) combined with circulating 
microbubbles has been investigated as a method to more safely disrupt the BBB. The exact 
mechanism by which microbubble-enhanced FUS leads to BBB disruption remains 
unknown. Current understanding is that either FUS/microbubble interactions stretch the 
endothelium similar to hyperosmotic solutions or trigger a physiological response that 
leads to temporary BBB breakdown (63). Nevertheless, FUS has garnered considerable 
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interest because it offers the potential to control the spatial location as well as the 
magnitude of BBB disruption through modification of the ultrasound parameters. 
Furthermore, the procedure can be easily repeated and is non-invasive. Recent studies in 
non-human primates have not shown the significant side effects observed for widespread 
BBB disruption (64). A pilot clinical trial using FUS to delivery doxorubicin to GBM 
patients has been completed, and a number of clinical trials are underway to investigate 
FUS in other brain diseases (65). Results from these trials are not yet available. In addition 
to efficacy, of particular concern is the long-term safety of this method in humans. 
1.3.3 Exploiting endogenous solute transport systems at the BBB 
Compared to the invasive, local strategies detailed above, therapeutics that are 
capable of entering the brain from circulation by using endogenous transport systems 
(detailed in section 1.2.2) offer a distinct advantage in treating diffuse brain diseases, 
including: (i) metastatic cancers with multiple foci, (ii) fingers of gliomas and (iii) 
neurodegenerative diseases. The human brain contains about 400 miles of blood vessels, 
corresponding to a total surface area for exchange near 20 m2. Additionally, no cell in the 
brain is more than 25 µm away from a blood vessel, allowing for significantly shorter 
diffusional distances to reach the disease target compared to locally administered drugs 
(40). Even a macromolecular protein will diffuse this distance in less than a second (66).  
Some small molecules are able to reach the brain through PTD. However, the 
molecular properties that favor PTD transport are significantly more restricted than those 
typically used to design small molecule drugs (Fig. 1.6). Generally, brain penetrant small 
molecules require a: (i) low molecular weight (<450 Da), (ii) limited polar surface area 
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(<60-80 Å2), (iii) moderate lipophilicity (logP<5), (iv) neutral or basic pKa (7.5-10.5) and 
(v) limited number of hydrogen bond donors and acceptors (<7) (67). The vast majority of 
small molecule therapeutics do not meet these criteria, and are therefore ineffective in the 
treatment of brain diseases due to their low brain permeability. 
 
Fig. 1.6. Molecular properties that allow for small molecule drug brain penetration impose 
tight restrictions on drug design, particularly molecular weight and total polar surface area.   
Another aspect affecting small molecule drug delivery to the brain – either 
systemically or by invasively bypassing or disrupting the BBB – is the presence of efflux 
pumps on the basal side of the endothelium. Specific ATP-binding cassette (ABC) efflux 
transporters exist to clear neurotoxins from the brain parenchyma, including: (i) p-
glycoprotein, (ii) multidrug resistance-associated proteins and (iii) breast cancer-resistance 
protein (68). In fact, most small molecule chemotherapeutics have been shown to be 
substrates of one or more of these ABC transporters (69,70). Thus, small molecule drugs 
for the treatment of brain diseases must be designed not only for brain penetration, but also 
evasion of efflux pumps, severely limiting the treatment options using PTD.  
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Drug delivery using SCPs requires mimicking the endogenous small molecule 
ligand or conjugation of the drug to the substrate. This approach can be successful for small 
molecule drugs, such as gabapentin and L-dopa, both of which are primarily shuttled into 
the brain by the large neutral amino acid transporter (LAT1) (71,72). However, as with 
PTD, the potential chemistries compatible with SCPs are fairly limited, and neither 
approach is conductive to transport of large, macromolecular therapeutics, such as potent 
biologics and nanoscale drug delivery systems. 
Of the endogenous transport mechanisms at the BBB, only the transcytosis 
pathways are compatible with delivery of macromolecular agents. Drug targeting using 
AMT relies on chemical modifications, such as polyamination of proteins, to increase their 
positive charge (73). However, the nonspecific nature of AMT severely limits its 
therapeutic potential, as broad cellular uptake can lead to off-target toxicities as well as 
less favorable pharmacokinetic properties. Additionally, positively charged compounds are 
known to disrupt the BBB (74), calling into question the safety of this approach as a means 
of increasing brain penetration. 
Unlike AMT, the RMT pathway is highly specific. The idea of using this 
mechanism to shuttle therapeutics into the brain was proposed decades ago (40). The 
general approach has been to conjugate the drug to a ligand that binds a transcytosing 
receptor at the BBB endothelium. Binding of the ligand portion of the ligand-drug 
conjugate facilitates its transit across the BBB in the transcytosing vesicle. Then, once 
released in the brain, the drug can diffuse to its target. This strategy of “masking” the 
therapeutic has been dubbed the “Trojan-horse” approach to smuggling drugs into the brain 
(40). RMT across the BBB has already been investigated to deliver a variety of payloads 
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to the brain, including: (i) protein-drug conjugates (75), (ii) therapeutic antibodies (76), 
(iii) liposomes (77) and (iv) nanoparticles (78,79). 
1.4 Transferrin receptor (TfR)-targeted drug delivery to the brain  
1.4.1 Receptor-mediated transcytosis (RMT) of transferrin (Tf) 
Several receptors are known to undergo RMT at the BBB endothelium, and have 
been investigated for targeted drug delivery to the brain, including: (i) insulin receptor 
(InsR), (ii) transferrin receptor (TfR), (iii) low-density lipoprotein receptor-related protein 
1 (LRP1) and (iv) folate receptor (80). Of these, the TfR pathway has been one of the most 
widely explored RMT systems for drug delivery. 
TfR is a transmembrane homodimer of two glycoprotein subunits that regulates 
intracellular delivery of iron (81). Each TfR subunit can bind one iron-carrying Tf ligand 
(82). In most epithelial cells, binding of iron-loaded Tf (holo-Tf) triggers clathrin-mediated 
endocytosis of the protein-receptor complex. A drop in pH (to pH 5.5) within the endosome 
causes a conformation change in Tf, leading to the release of iron into the endosomal 
compartment and recycling of apo-Tf (Tf without bound iron) to the cell surface. The 
decreased affinity of apo-Tf for TfR at extracellular pH allows for its release from the 
receptor (83) (Fig. 1.7). 
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Fig. 1.7. Endocytic recycling of TfR in apolar cells. (i) Holo-Tf carrying two Fe3+ atoms 
binds TfR on the plasma membrane. (ii) Binding induces endocytosis of the Tf:TfR 
complex. (iii) Protons are actively pumped into the endosome, reducing the pH to ~5.5. 
(iv) Acidification of the endosome triggers a conformational change in Tf, leading to 
release of bound iron. (v) Recycling of TfR to the cell surface allows for release of iron-
free Tf (apo-Tf). 
In polarized cells such as the BBB endothelium, this process is slightly modified to 
allow Tf to enter the brain. After endocytosis, intracellular machinery sorts the Tf-
containing vesicle to the transcytosis pathway, routing it across the cell to the basal 
membrane (83,84). Although there is still debate regarding the exact mechanism by which 
Tf is sorted to undergo transcytosis, it is well-established that Tf must undergo some 
portion of endocytosis before diverting to transcytosis (85,86).  
TfR-targeting is an attractive strategy for drug delivery to the brain because it is 
highly expressed on the BBB endothelium (81). TfR is similarly upregulated in many 
cancers, and has been successfully targeted by siRNA-containing nanoparticles in clinical 
trials (88). Additionally, TfR at the BBB is not saturated by endogenous Tf, as seen in other 
tissues, providing accessible binding sites for targeted therapeutics (89). Thus, many 
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groups have attempted to exploit this pathway by either developing antibodies to TfR or 
targeting with the Tf ligand. 
1.4.2 Drug delivery across the BBB using anti-TfR antibodies (Abs) 
Anti-TfR Abs have garnered the most interest because of their ability to bind TfR 
with high affinity and specificity as well as their ability to trigger endocytosis through 
binding of a different epitope than endogenous Tf (83,90). Pioneering studies in the early 
1990s with an Ab against the rat TfR (OX26) were among the first to show that an anti-
TfR Ab could cross the BBB and enter the brain (91,92). Several practical limitations, 
however, prevented the translation of these early studies to the clinic. Of particular concern 
was the observation that a majority of the Abs accumulated in the BBB endothelium, 
instead of penetrating the brain (93). The authors discussed the possibility of high-affinity 
Ab:TfR interactions preventing the release of OX26 into the brain following transcytosis, 
evidence for which would come many years later. 
Subsequent studies began to uncover the mechanisms preventing accumulation of 
large numbers of anti-TfR Abs in the brain, leading to a resurgence in interest in the 
delivery strategy. The first of these studies showed that reducing the affinity of anti-TfR 
Abs to TfR maximizes their uptake into the brain parenchyma (94). The authors proposed 
that high-affinity Abs induce transcytosis, but remain bound to TfR once the vesicle fuses 
to the basal endothelium, and are thus unable to penetrate the brain while lower-affinity 
variants could dissociate from TfR because of their reduced affinity (Fig. 1.8). With this 
approach, they were able to deliver nearly 1% of the lower-affinity anti-TfR Ab to the brain 
parenchyma, an amount deemed therapeutically useful (94). However, this level of 
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accumulation required extraordinarily high systemic doses – a cause for concern in future 
translational studies. 
 
Fig. 1.8. Inverse relationship between the affinity of anti-TfR Abs and their brain uptake. 
High-affinity Abs transcytose the BBB endothelium, but are restricted from entering the 
brain by the strong Ab:TfR interactions (A), whereas lower-affinity variants can 
accumulate in the brain in greater numbers if administered at very high doses (B). TJ, tight 
junction. 
Further investigation revealed that while greater brain exposure of anti-TfR Abs is 
achieved as the affinity for TfR is reduced, a different mechanism is at play – affinity 
influences the intracellular trafficking of anti-TfR Abs. High-affinity anti-TfR Abs are 
trafficked to the lysosome, while lower-affinity variants are more capable of transcytosis 
(95) (Fig. 1.9). Around the same time, it was shown that bivalent Ab:TfR binding also leads 
to lysosomal sorting, whereas monovalent binding facilitates transcytosis (96) (Fig. 1.10). 
Furthermore, recent evidence indicates that intracellular tubules mediate this sorting 
mechanism (97).  
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Fig. 1.9. Mechanism for decreased brain exposure of high-affinity anti-TfR Abs. High-
affinity Abs are sorted to the lysosome for degradation (A), whereas lower-affinity variants 
may be transcytosed to the brain parenchyma (B). 
 
Fig. 1.10. Binding valency effect on intracellular sorting and transcytosis capacity of anti-
TfR Abs. Bivalent Ab:TfR binding induces abnormal configuration of TfR and trafficking 
to the lysosome (A), whereas monovalent binding preserves natural trafficking, allowing 
for Ab transcytosis (B).  
In addition to affinity and valency, recent in vitro results suggest that pH-sensitivity 
of TfR binding also affects intracellular trafficking of anti-TfR Abs; an Ab with reduced 
affinity at endosomal pH 5.5 showed a greater ability to transcytose than pH-independent 
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Abs of comparable affinities at extracellular pH 7.4 (98). These data suggest an approach 
in addition to reducing binding affinity that may facilitate greater brain parenchyma uptake 
of anti-TfR Abs – pH-dependent binding to TfR. 
Despite a thorough understanding of the properties that favor transcytosis, several 
challenges exist in translating anti-TfR Abs into the clinic, including the need to: (i) dose 
very high quantities (90), (ii) mitigate effector-function driven safety concerns (99) and 
(iii) develop species-specific Abs (100). 
1.4.3 Transport of TfR-targeted gold nanoparticles at the BBB 
Motivated by the results from anti-TfR Ab trafficking at the BBB, our group began to 
investigate how fundamental aspects of TfR-targeted nanoparticle design affect transcytosis 
capacity, namely: (i) nanoparticle size, (ii) charge and (iii) targeting ligand density (101). 
Targeted nanoparticles were chosen for their ability to deliver large quantities and a variety of 
drugs to specific tissues at well-controlled release rates (detailed in section 1.5) (102). Initially, 
gold nanoparticles (AuNPs) of varying diameters (ca. 20-80 nm) were prepared with increasing 
quantities of Tf on the surface and assessed for their ability to enter the brain in mice. Zeta 
potentials of all formulations were kept near neutral by adding a dense polyethylene glycol 
(PEG) coating to the gold surface because it has been shown that near neutral to slightly anionic 
particles do not compromise BBB integrity, unlike cationic formulations (74).  
In analogy to the results obtained with anti-TfR Abs, the authors found that Tf-coated 
AuNPs with reduced avidity to TfR showed the greatest ability to cross the BBB (101). As 
was initially proposed for anti-TfR Abs, they hypothesized that the numerous, multidentate 
Tf:TfR interactions with the high-avidity formulations prevented their release into the brain, 
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while the lower-avidity formulations we able to complete the transcytosis process (Fig. 1.11). 
Interestingly, high-avidity, Tf-coated AuNPs were not seen within lysosomes using 
transmission electron microscopy (TEM) (101), indicating that vesicle trafficking may be 
affected by the particular targeting ligand. Furthermore, in contrast to anti-TfR Abs, these 
data suggest that the limiting factor in delivering Tf-coated AuNPs may not be sequestration 
to the lysosome, and that targeting TfR with its endogenous ligand may help promote 
transcytosis. Despite showing promise, questions regarding the need for very high systemic 
dosing to achieve sufficient brain accumulation led to alternative nanoparticle designs.  
 
Fig. 1.11. Tf-coated nanoparticles are similarly constrained at the BBB compared to anti-
TfR Abs. (A) High-avidity AuNPs are held up by the BBB endothelium, whereas (B) 
lower-avidity AuNPs can accumulate in the brain in greater amounts, but only with very 
high systemic dosing. 
Recently, our group incorporated an acid-cleavable targeting strategy into the 
nanoparticle design to increase the ability of high-avidity nanoparticles to enter the brain 
(79). With this design, nanoparticles can bind TfR with high avidity on the blood side of 
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the BBB to enable practical, systemic dosing, but shed the targeting ligands upon 
acidification during transcytosis (83,103), allowing free diffusion into the parenchyma 
(Fig. 1.12). Incorporation of an acid-cleavable linkage between Tf and the nanoparticle 
core increased brain accumulation of high-avidity Tf-coated AuNPs nearly 3-fold (79). In 
contrast, no improvement was observed with high-affinity anti-TfR-coated AuNPs with the 
cleavable linker, consistent with their trafficking to the lysosome. These results further 
bolster the hypothesis that intracellular trafficking may be affected by the particular 
targeting ligand, and demonstrate the utility of the acid-cleavable targeting scheme to 
increase brain penetration of nanoparticles. 
 
Fig. 1.12. Acid-cleavable targeting strategy to increase brain uptake of high-avidity 
nanoparticles. (i) High-avidity Tf-coated AuNPs readily bind TfR on the blood side of the 
BBB, inducing endocytosis of the Tf-coated AuNP:TfR complex. (ii) Protons are actively 
pumped into the endosome, reducing the pH to ~5.5. (iii) Acidification of the endosome 
triggers detachment of Tf from the AuNP surface. (iv) Vesicle fusion with the basal 
membrane allows for free diffusion of the AuNP into the brain parenchyma. 
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1.5 Nanoparticle drug delivery systems  
 Nanoparticles have garnered tremendous interest in the medical community over 
the last several decades. They offer several distinct advantages for drug delivery over 
standard therapeutics, including their ability to: (i) improve the pharmacologic profile of a 
drug without altering the molecule itself, (ii) be loaded with large quantities of drug 
compared to ligand-drug conjugates (by several orders of magnitude), (ii) release drugs at 
a tunable rate, (iv) deliver multiple therapeutic agents simultaneously at controlled ratios 
and (v) accumulate within specific tissues, thereby enhancing efficacy and minimizing off-
target toxicities (102). Moreover, nanoparticles have proven clinical efficacy, with several 
formulations receiving FDA approval and on the market, and hundreds more in various 
stages of preclinical and clinical development for cancer therapy (104). 
 1.5.1 Polymeric nanoparticle formulations 
 In particular, there is growing optimism for polymeric nanoparticle formulations 
(105-107). The versatility of polymer chemistry has enabled the development of different 
types of nanoparticle systems to either encapsulate or covalently attach active drug 
molecules with distinct physiochemical structures and properties. Several FDA-approved 
polymers, such as N-(2-hydroxypropyl)methacrylamide (HPMA), poly(lactic acid) (PLA), 
poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), and polyethylene glycol 
(PEG) have been developed for these delivery systems (107). The most common polymeric 
nanoparticle platforms include solid polymeric nanoparticles, polymeric micelles, 
polymersomes, dendrimers, and polymer-drug conjugates (Fig. 1.13). 
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Fig. 1.13. Types of polymeric nanoparticle systems for drug delivery. Gray denotes 
polymeric material and orange active drug. (A) Solid polymeric nanoparticles are carriers 
in which a drug is encapsulated in a polymer matrix. (B) Polymeric micelles are formed by 
amphiphilic di- or tri-block copolymers, resulting in a core/shell structure. Drugs are 
encapsulated within the hydrophobic core. (C) Polymersomes are polymeric analogs of 
liposomes. Amphiphilic block copolymers assemble a lipid bilayer-like structure, 
enclosing an aqueous core containing drug molecules. (D) Dendrimers are synthetic, 
branched polymeric macromolecules that form star-like structures. Typically, drug 
molecules are conjugated to the scaffold. (E) Polymer-drug conjugates are formulations 
where one or more drug(s) is covalently attached to a linear, hydrophilic polymer. The 
amphiphilic nature of the conjugate material (hydrophilic polymer/hydrophobic drug) 
often drives its assembly into nanoparticles in aqueous media. 
 Of these polymeric nanoparticle systems, polymer-drug conjugates are the most 
actively explored (102,108,109) and are of greatest relevance to this work. The covalent 
bond between the polymer and drug offers significant opportunity for greater control of 
drug release through design of specific chemical linkers. Moreover, higher drug loadings 
can generally be achieved with polymer-drug conjugates compared to encapsulation 
techniques, thereby enhancing the potency of nanoparticles that reach the site of disease 
(110). However, this platform also comes with challenges, as not all drugs have functional 
groups that allow for simple, reversible covalent conjugation (detailed in Appendix A). 
Nevertheless, polymer-drug conjugates remain an attractive delivery platform, and many 
have been successfully translated to the clinic for cancer therapy (108,109), including 
CRLX101 (IT-101), a nanoparticle therapeutic developed in our group (111). 
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1.5.2 Passive and active targeting of nanoparticles 
As mentioned, one of the advantages of nanoparticle therapeutics is their ability to 
achieve preferential accumulation in targeted tissues or cells. Two approaches are primarily 
used to facilitate nanoparticle homing to the desired site: passive and active targeting. 
Passive targeting involves the use of disease-specific features such as enhanced vascular 
permeability in tumors, whereas active targeting is achieved by adding a targeting ligand 
to the surface of nanoparticles to direct preferential accumulation (102). A number of types 
of affinity ligands have been explored for active targeting of polymeric nanoparticles, 
including peptides and antibodies (112,113). The targeting agent enables nanoparticle 
binding to extracellular matrix proteins in the diseased tissue or to antigens on the plasma 
membrane of target cells, facilitating their endocytic internalization (102). Moreover, 
actively-targeted nanoparticles have proven more effective than their non-targeted 
counterparts, largely due to their ability to be retained by target cells and locally release 
the drug (114). 
1.5.3 Stimuli-responsive systems 
 Stimuli-responsive systems add a further level of refinement to these nanoparticle 
formulations. The general approach has been to design systems that have the ability to 
respond to environmental changes at the site of action (e.g. pH, temperature), triggering 
destabilization or degradation and allowing release of the drug (102). Many types of 
stimuli-responsive nanomedicines have been developed (115,116), with some reaching 
clinical trials (117). For polymeric nanoparticles, stimuli-responsive chemistry has been 
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incorporated both at the point of attachment of stabilizing polymers or within the polymer 
chain itself (118,119). However, our acid cleavable targeting strategy (79) that was 
developed to improve the ability of high-avidity nanoparticles to enter the brain is the first 
demonstration of using stimuli-responsive chemistry to facilitate intact nanoparticle transit 
across cellular barriers.  
1.6 Thesis objectives and organization 
Previous studies showed that attaching TfR-targeting ligands to the nanoparticle 
core via a link that would cleave during BBB transcytosis could enable high-avidity AuNPs 
to cross the BBB and accumulate in the brain. However, the acid-cleavable linker 
investigated did not provide optimal cleavage kinetics to remove all the targeting ligand 
during transcytosis (79). The goal of this work was to determine whether TfR-targeted, 
polymer-drug conjugate nanoparticles using an improved acid-cleavable chemistry could 
be used to deliver pharmacologically active amounts of drug to the brain parenchyma (Fig. 
1.14). 
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Fig. 1.14. Brain delivery of TfR-targeted, therapeutic nanoparticles using improved acid-
cleavable targeting chemistry. Following endocytosis of the nanoparticle, acidification of 
the endosome occurs within minutes (120). Tf has been shown to transcytose within 30 
minutes of systemic injection (121). Thus, for optimal transcytosis, TfR-targeting ligands 
must cleave on the order of tens of minutes within the acidified endosome to release the 
nanoparticle core. Additionally, the polymer-drug conjugate linker within the core must 
remain stable within this timeframe to allow for delivery of intact nanoparticles to the brain 
and their subsequent diffusion into the parenchyma. 
 First, in an attempt to create a clinically representative, non-permissive barrier to 
standard therapeutics, a new murine model of HER2-positive breast cancer brain metastasis 
was developed that more closely resembles human brain metastasis development (Chapter 
II). Initial characterization revealed that brain metastases established by this new method 
were not responsive to standard HER2-targeted agents, replicating the clinical situation. 
 Next, the newly developed model as well as two common models from the literature 
were used to evaluate the efficacy and brain uptake of TfR-targeted, single-agent 
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therapeutic nanoparticles (Chapter III). TfR-targeted, therapeutic nanoparticles showed 
significant accumulation in brain metastases, and led to improved antitumor activity 
compared with free drug and non-targeted nanoparticles across all models investigated. 
Furthermore, TfR-targeted nanoparticles showed an increased ability to cross an intact 
BBB, resulting in whole-brain penetration. Additionally, a significant antitumor response 
as well as brain tumor accumulation of non-BBB-penetrant small molecule and non-
targeted nanoparticle therapeutics were observed in the most commonly used model from 
the literature. Both the new model and one emerging in the literature provided for a more 
intact BBB/BTB. These data show that the method of establishing metastatic brain tumors 
can dramatically affect the efficacy of therapeutics and their brain penetration. 
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Chapter II 
DEVELOPMENT OF MOUSE MODEL THAT REPLICATES  
THE METASTASIS PROCESS IN HER2-POSITIVE BREAST 
 CANCER BRAIN METASTASIS PATIENTS* 
*Excerpts from this chapter are reprinted from Wyatt EA, Davis ME (2018) Method of establishing breast 
cancer brain metastases affects brain uptake of targeted, therapeutic nanoparticles. Bioengineering and 
Translational Medicine 1–8 with permissions from Bioeng Transl Med. 
2.1 Introduction 
2.1.1 HER2-positive breast cancer brain metastasis 
Human epidermal growth factor receptor 2 (HER2) protein overexpression is 
observed in about 25% of human breast cancers. It confers a more aggressive phenotype 
and, historically, has been associated with poor patient prognosis (1). HER2-targeted 
therapies, such as the anti-HER2 antibody (Ab) trastuzumab, have improved outcomes in 
patients with HER2-positive, metastatic disease. However, with improved control of 
systemic disease and prolonged survival, the incidence of brain metastases is increasing in 
these patients (2,3). Currently, as many as half of patients with HER2-positive, metastatic 
breast cancer develop brain metastases over time (4). Treatment of these brain tumors is a 
growing clinical challenge, in large part due to the poor penetration of HER2-targeted 
agents through the blood-brain barrier (BBB) (4). 
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2.1.2 The BBB/BTB debate 
There is considerable debate in the literature regarding the extent to which the BBB 
remains intact with brain metastases (in the form of the blood-tumor barrier (BTB)). 
Contrast agents show enhanced uptake in brain metastases, but chemotherapy has been 
generally ineffective in the clinic (5). Recent studies in experimental brain metastasis 
models reveal that, although the majority of metastases have some increased vascular 
permeability, their uptake of chemotherapeutics is limited (6). Furthermore, significant 
heterogeneity in therapeutic uptake is observed in brain metastases resected from patients, 
both among patients and within individual lesions (7). Additionally, an investigation of 
breast cancer subtypes showed that there is no significant disruption of the barrier by brain 
metastases resected from patients with HER2-positive breast cancer (8). Thus, while brain 
metastases may have some increased permeability, approaches to overcome limited drug 
delivery to the brain will be important to improve clinical outcomes, particularly for HER2-
positive, metastatic disease. 
2.1.3 Animal models of breast cancer brain metastasis 
Mouse models of breast cancer brain metastasis are needed to both identify the 
biological mechanisms that contribute to the disease pathogenesis as well as to evaluate 
potential treatment strategies (9), including investigation of new approaches to increase the 
brain penetration of therapeutic agents. One of the most widely used methods to study 
breast cancer brain metastasis involves direct injection of human breast cancer cells into 
the mouse brain parenchyma (Fig. 2.1A). This intracranial (IC) model provides important 
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insight into specific molecular events and pathways associated with tumor progression, as 
well as the utility of particular combination therapies (10, 11). However, because antitumor 
response to non-BBB-penetrant therapeutics has been observed in this model (10,11), we 
hypothesized that this method of establishing breast cancer brain metastases may not 
provide a clinically relevant, impermeable BBB/BTB to traditional therapeutic agents, thus 
limiting its usefulness for our investigation of nanoparticle delivery across the BBB/BTB 
to breast cancer brain metastases.  
 
Fig. 2.1. Illustration of breast cancer brain metastasis models. (A) Intracranial (IC) 
injection of tumor cells allows for direct establishment of brain metastases. (B) Following 
intracardiac (ICD) injection into the left ventricle, tumor cells can head to brain 
vasculature, as well as to other organs. Some cells will successfully extravasate and form 
macroscopic brain tumors. (C) After intravenous (IV) injection, most tumor cells will arrest 
in the lung capillary bed, as well as other sites, followed by subsequent metastasis to the 
brain. 
 The preclinical study of fully metastatic breast cancer brain metastases in murine 
models has been limited by the fact that, in most cases, human breast cancer cell lines 
derived from metastatic tumors fail to consistently metastasize in immunodeficient mice, 
such as nude mice (12-14). Furthermore, tumor foci only occasionally form in the brain, 
limiting the practicality of this approach. Recently, it has been shown that modifications to 
the experimental conditions can increase the propensity of breast cancer cells to 
metastasize to the brain in mice, such as using special injection routes (e.g. intracardiac 
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(ICD), Fig. 2.1B) or developing cell variants with specific organ tropism (e.g. brain-tropic 
metastatic breast cancer cells) (15-17). However, such modifications can give rise to 
preclinical models that are further removed from clinical relevance and lack critical aspects 
of the human disease. For example, although brain metastases are most commonly 
observed among HER2-positive metastatic breast cancer patients, the majority of 
preclinical studies are based on established “brain-seeking” breast cancer cell lines that are 
HER2-negative, particularly brain-colonizing sublines of the human MDA-MB-231 breast 
cancer cell line (18,19). 
As an alternative to manipulating human-derived breast cancer cells lines, a more 
permissive host can be used that may allow for improved metastatic dissemination. 
Evidence suggests that natural killer (NK) cells play a critical role in preventing metastatic 
spread of tumor cells in classical nude mice (20). Pretreatment of nude mice with NK-
depleting antibodies was initially investigated as a potential solution to allow for metastatic 
dissemination of cancer cells (21); however, this only provided a narrow temporal window 
of inhibited NK activity that was not sufficient for lengthier studies of metastasis, such as 
dissemination from local tumors. Recently, Rag2-/-;Il2rg-/- mice that lack B, T, and NK cells 
(22) have shown the ability to permit the systemic spread of several human cancer cell 
types without the need for additional modification of the cancer cells (cite sarcoma and 
breast papers) (21,23).  
Here, we present a new murine model for HER2-positive breast cancer brain 
metastasis that involves intravenous (IV) injection of breast cancer cells in Rag2-/-;Il2rg-/- 
mice (Fig. 2.1C). This new model developed here establishes brain metastases by methods 
that more closely resemble the human disease, forming whole-body tumors that eventually 
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metastasize to the brain. Our results suggest that IV-formed brain tumors maintain a more 
intact BBB/BTB than those established by IC injection, enabling future studies that 
investigate new strategies to increase brain uptake of therapeutics.  
2.2 Results and discussion 
2.2.1 Rag2-/-; Il2rg-/- mice are permissive to brain metastasis following IV 
injection of HER2-positive BT474-Gluc breast cancer cells 
 In an attempt to create a clinically representative, impermeable barrier to standard 
therapeutics, we developed a new model of HER2-positive breast cancer brain metastasis 
that reproduces human cancer dissemination. HER2-positive BT474-Gluc cells were IV 
injected into Rag2-/-;Il2rg-/- mice, and formation of brain metastases was monitored by 
MRI. This cell line was engineered to express cerulean fluorescent protein (CFP) and 
Gaussia luciferase (Gluc) that can be used as a surrogate for tumor burden (24). Rag2-/-;     
Il2rg-/- mice were chosen because they have shown the ability to allow multi-organ 
metastatic spread of HER2-positive breast cancer cell lines injected IV (23).  
 After IV injection, BT474-Gluc brain tumors developed in a majority of the mice 
(> 90%) before they succumbed to visceral tumor burden, with a distribution similar to that 
observed in patients (Fig. 2.2). The median time to establishment of brain metastatic tumors 
visible by MRI was 4.2 months (range 2.9 – 6.1 months). 
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Fig. 2.2. Metastatic brain tumors imaged by MRI following IV injection of BT474-Gluc 
cells. Intracerebral (A,B,C) and leptomeningeal metastases were detected (D). Most 
intracerebral metastases were located in the cerebrum (A), with occasional metastases in 
the cerebellum (B). Multifocal metastases were occasionally observed (C). 
Leptomeningeal metastases most commonly grew in the subarachnoid space (D). Scale bar, 
2 mm. 
2.2.2 Brain tumors display differential morphology and response to standard 
HER2-targeted therapy when established by IV versus IC method 
We compared BT474-Gluc brain metastatic tumors established by the IV method 
versus the standard IC method in Rag2-/-;Il2rg-/- mice. After IV or IC injection of BT474-
Gluc cells, formation of brain metastatic tumors was monitored by MRI. Interestingly, 
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when compared to IC-formed metastases, brain tumors established by IV injection 
displayed more uniform MRI contrast and an increased invasive phenotype by infiltrating 
rather than displacing neighboring brain regions (Fig. 2.3). Furthermore, a marked increase 
in necrotic fraction of the tumor tissue was observed for tumors established by IC injection 
relative to IV injection. 
 
Fig. 2.3. Growth of BT474-Gluc metastatic brain tumors when established by IC and IV 
injection of breast cancer cells, as monitored by MRI. (A) IC-formed brain tumors. (B) IV-
formed brain tumors. Scale bar, 2 mm. 
Additionally, we examined the vasculature in BT474-Gluc brain metastatic tumor 
tissue following IV- and IC-establishment. 1 mm-thick tissue sections of brain tumor and 
healthy brain tissue were prepared using the CLARITY method for clearing large tissue 
volumes (25). Tissue samples were nuclear stained with DAPI as well as immunostained 
with an antibody against CD31, and imaged using confocal microscopy. In both tumor 
models, imaging studies revealed marked abnormality and significant increase in diameter 
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of the tumor vasculature relative to healthy brain vasculature (Fig. 2.4). These observations 
are consistent with previous reports that suggest perivascular growth of HER2-positive 
breast cancer brain metastases is angiogenic (26). Tumor vasculature in IC-formed brain 
tumors was more irregular (e.g. forming abnormal loops), as compared to that in IV-formed 
brain tumors that showed more regular branching.  
 
Fig. 2.4. Confocal images of CLARITY processed Rag2-/-;Il2rg-/- healthy and tumor brain 
vasculature. Provided are representative volume renderings (left) and 200 μm thick 
maximum intensity projections (MIPs) centered at 500 μm depth (right) for healthy brain 
tissue (A), IC-formed brain tumor tissue (B) and IV-formed brain tumor tissue (C). In 
addition to endogenous tumor marker (CFP), tissue was nuclear stained (DAPI) as well as 
vascular immunostained (CD31). Scale bar, 100 μm.  
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Most importantly, we tested the effects of a standard anti-HER2 therapy, 
trastuzumab, on the growth of BT474-Gluc tumors established by IV injection versus the 
commonly used IC method. Trastuzumab at 5 mg/kg was administered twice weekly via 
intravenous tail vein injection, and treatment was initiated when tumors reached 10 mm3 
in volume. MRI was used to monitor brain tumor size and response to therapy. Treatment 
with trastuzumab led to delay in tumor progression when tumors were established by IC 
injection, suggesting this method of forming brain tumors may disrupt the BBB/BTB (Fig. 
2.5). In contrast, trastuzumab failed to control tumor growth for tumors established IV, 
mimicking the clinical situation. Similarly, treatment with lapatinib did not slow tumor 
progression for IV-formed tumors. 
 
Fig. 2.5. Effect of anti-HER2 therapy on HER2-positive BT474-Gluc breast cancer brain 
metastases established in Rag2-/-;Il2rg-/- mice. Tumors established by IC injection (A) 
showed significant delay in tumor progression, whereas those established by IV injection 
(B) did not. Data shown are 4 mice per treatment group for the IC model, and 8, 12 and 2 
mice for saline, trastuzumab and lapatinib groups, respectively, for the IV model.  
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2.2.3 IV model of HER2-positive breast cancer brain metastasis reproduces 
metastatic pattern observed in patients 
To assess the metastatic spread of BT474-Gluc breast cancer cells in Rag2-/-;     
Il2rg-/- mice following IV injection, all organs were collected for analysis and metastases 
were identified using a number of methods. A hematoxylin and eosin (H&E) stain was 
performed first on thin-fixed tissue samples to identify potential tumor foci (Fig. 2.6A). 
Subsequently, BT474-Gluc metastases were confirmed using two methods, including: (i) 
immunohistochemistry by staining for HER2 overexpression, and (ii) confocal microscopy 
by presence of tumor-associated CFP (Fig. 2.6B and C). CLARITY was also performed to 
assess tumor burden in large volumes of tissue (Fig. 2.6D). Notably, IV injection of BT474-
Gluc cells reproduced the full metastatic pattern observed in breast cancer patients, with 
multiple metastatic sites including brain, lung, bone, liver, ovary and lymph tissues among 
others (Table 2.1). 
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Fig. 2.6. Metastasis identification in Rag2-/-;Il2rg-/- mice following IV injection of BT474-
Gluc breast cancer cells. Thin-fixed tissue sections were analyzed by H&E histology (A), 
HER2 immunohistochemistry (B), and confocal microscopy (C). Large tissue volumes were 
CLARITY processed, nuclear stained (Draq5) and imaged by confocal microscopy (D). 
Provided are a full volume rendering and 200 μm thick MIPs compared to a thin-fixed section 
(left), and higher magnification of an individual metastasis (right). The results shown here 
for lung tissue are indicative of the observations in the other tissue types. Scale bar, 100 μm. 
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Table 2.1. Metastatic ability of human BT474-Gluc breast cancer cells in Rag2-/-;Il2rg-/- 
mice following IV injection. Metastasis incidence provided by site per number of mice for 
which tissue type was analyzed. *Other metastatic sites included kidney, salivary glands, 
and interscapular space. 
2.3 Conclusions 
 
Here, we describe a new preclinical model of human HER2-positive breast cancer 
brain metastasis based on an immunodeficient Rag2-/-;Il2rg-/- mouse that lacks B, T, and 
NK cell activity. This more permissive host enabled complete, multiorgan metastatic 
spread of HER2-positive BT474-Gluc human breast cancer cells, without the need for 
selections or additional modifications to the system. Importantly, BT474-Gluc cells 
injected intravenously consistently metastasized to the brain, allowing the study of brain 
metastatic tumors before the mice succumbed to systemic tumor burden. Additionally, we 
show that brain metastases formed by IV injection of breast cancer cells differ from those 
established by the commonly used IC method. We observed a significant antitumor 
response to a standard anti-HER2 agent in brain tumors that were formed by IC injection 
of human breast cancer cells. In contrast, the HER2-inhibitor failed to control tumor growth 
in metastases established by the IV method, replicating the clinical situation. 
After our development work was completed, the model that uses an ICD injection 
to establish brain metastases gained popularity in the literature. Thus, we included both 
commonly used models from the literature in addition to our new model here to investigate 
the efficacy and brain penetration of targeted, therapeutic nanoparticles.  
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2.4 Materials and methods 
IC and IV Brain Metastasis Models. All animals were treated according to the NIH 
guidelines for animal care and use as approved by the Caltech Institutional Animal Care 
and Use Committee (27). BT474-Gluc cells, transduced with an expression cassette 
encoding Gluc and CFP separated by an internal ribosomal entry site using a lentiviral 
vector, were obtained from Dr. Jain at Harvard University. BT474-Gluc cells were 
maintained in RPMI 1640 supplemented with 10% (v/v) FBS in a humidified oven at 37°C 
with 5% CO2. For the IC model, 50,000 BT474-Gluc cells in 2 µL RPMI were 
intracranially injected into the right cerebral hemisphere of female Rag2-/-;Il2rg-/- mice 
(Jackson Laboratory) using a stereotaxic apparatus at a rate of 0.1 µL/min. The coordinates 
for injection were 2 mm posterior, 1.5 mm lateral to bregma, and 2.5 mm depth from 
bregma. For the IV model, 2 M cells were suspended in 150 µL RPMI and slowly injected 
into the lateral tail vein of restrained female Rag2-/-;Il2rg-/- mice. 
Tumor Size Monitoring. For the IV model, formation of BT474-Gluc brain metastatic 
tumors was monitored by MRI on a 11.7-T magnet every few weeks until macroscopic 
tumors were visible (~0.2 mm3 in volume). Tumor growth was then monitored by MRI 
approximately weekly, as for the IC model. Mice were anaesthetized with 1.5–2% (v/v) 
isoflurane in O2 at a flow rate of 1–1.5 mL/min. T2-weighted 3D RARE images were 
acquired to assess the tumor volume. The image acquisition parameters were as follows: 
echo time: 6.1 ms; repetition time: 250 ms; rapid acquisition relaxation enhanced (RARE) 
factor: 4; number of averages: 4; field of view: 2.0 cm x 1.2 cm x 0.8 cm; matrix: 200 x 
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120 x 80 (100 µm isotropic resolution). Tumor volume was determined manually from the 
T2 hyperintense tumor regions of the brain using Fiji software.  
Treatments. Treatment began when brain metastatic tumors reached ~10 mm3, as 
measured by MRI. Mice in the IC model were randomized into two groups of four mice 
per group. Mice in the IV model were randomized into two groups of 8 and 12 mice for 
the saline and Herceptin groups, respectively. Herceptin at 5 mg/kg was freshly prepared 
in PBS, pH 7.4. The control treatment was 0.9% (w/v) saline. The different formulations 
were systemically administered by lateral tail vein injection twice weekly with injections 
were standardized to 150 µL per 20 g body weight. Lapatinib was dissolved at 10 mg/mL 
in sterile water with 0.5% Tween 80 (Sigma) and administered at 100 mg/kg daily by oral 
gavage. 
Tissue Processing. Mice were sacrificed following signs of prolonged distress or loss of 
>20% body weight. The mice were anaesthetized and transcardially perfused with a 10% 
sucrose solution, followed by a 4% (v/v) formaldehyde in PBS, pH 7.4. All organs were 
collected for analysis. The freshly collected tissues were post-fixed in 4% (v/v) 
formaldehyde in PBS, pH 7.4 overnight at 4 °C, then washed in PBS, pH 7.4 with 0.02% 
NaN3 to remove excess fixative. Individual tissues were dehydrated in increasing 
concentrations of ethanol (3 x 30 min each for 50, 70, 95 and 100% EtOH), followed by 
xylenes (3 x 30 min) and 50:50 xylene:paraffin mixture (1 x 30 min). The tissues were then 
incubated in molten paraffin (3 x 1 h) at 60 °C, then placed in a paraffin mold and stored 
at 4 °C until sectioning. A Leica 1512 microtome was used to cut 5 μm sections. Slides 
were stored at 4 °C, protected from light until time for further processing. 
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H&E Histology. Paraffin-embedded sections were deparaffinized in xylenes, rehydrated 
using decreasing concentrations of ethanol and washed in pure water (3 x 1 min). Sections 
were stained in hematoxylin for 5 min, dipped in acidic EtOH, incubated in bluing agent 
(0.2% (v/v) ammonium hydroxide in water) for 2 min, and stained in eosin for 1 min with 
30 sec rinses in tap water between incubation steps. They were then dehydrated with 
increasing concentration of ethanol and xylenes. Tissues were mounted using Permount 
(Fisher) and images acquired on an Olympus IX50 microscope using a 10x CPlan objective 
and QCapture Pro 6 imaging software (QImaging). 
HER2 Tumor Biomarker Immunohistochemistry. Paraffin-embedded sections were 
deparaffinized in xylenes, rehydrated using decreasing concentrations of ethanol, and 
washed in pure water (3 x 1 min). Epitope retrieval was performed by baking the tissues at 
90-95°C in 10 mM citrate buffer, pH 6.0 for 40 min. The tissues were cooled for 20 min, 
then washed in PBST, endogenous peroxidase quenched with a 3% (v/v) hydrogen 
peroxide for 5 min, and rinsed again with PBST (2 x 5 min). For HER2 identification, 
tissues were incubated with a 1:100 dilution of an anti-human HER2 rabbit primary Ab 
(Dako A0485) in PBST for 1 h at room temperature, washed with PBST (2 x 5 min), 
followed by incubation with a 1:100 of a HRP-conjugated anti-rabbit goat secondary Ab 
(Abcam ab97051) in PBST for 1 h at room temperature, and finally washed with PBST (2 
x 5 min). Tissues sections were then developed with a DAB solution (Thermo Scientific) 
for 5 min at room temperature, rinsed with PBST (2 x 3 min), followed by counterstaining 
with hematoxylin for 2 min. Sections containing no primary Ab stain as well as no tumor 
were processed simultaneously and used as negative controls while samples known to 
  
60 
strongly express HER2 served as positive controls. Tissues were mounted using Prolong 
Gold antifade reagent and images acquired on an Olympus IX50 microscope using a 10x 
CPlan objective and QCapture Pro 6 imaging software (QImaging). 
CLARITY. Excised tissue was post-fixed in 4% (v/v) formaldehyde in PBS, pH 7.4 
overnight at 4 °C, then washed in PBS, pH 7.4 with 0.02% NaN3 to remove excess fixative. 
Tissue was sectioned on a vibratome to a thickness of 1 mm, and stored at 4 °C, protected 
from light until further processing. Tissues were incubated in A4P0 hydrogel monomer 
solution (4% acrylamide in PBS, pH 7.4) overnight with shaking (acrylamide solution, Bio-
Rad; thermal initiator, Wako). Samples were degassed, then polymerized in a 37 °C 
incubator for 3 h. Following polymerization, samples were washed in PBS, pH 7.4 to 
remove residual hydrogel, then cleared at 37 °C with gentle agitation in 8% (w/v) SDS 
with 0.02% NaN3 in PBS, pH 8.0 until optically transparent. Clearing times varied for 
tissue types. Samples were washed in PBS, pH 7.4 with 0.02% NaN3 for 2 days with 
minimum of four exchanges. Nuclear stained tissues were incubated in either a 1 μg/mL 
dilution of DAPI (Life Technologies) or a 1:1000 dilution of Draq5 (Cell Signaling) with 
0.02% NaN3 in PBST for 2 days with shaking, then washed in PBS, pH 7.4 with 0.02% 
NaN3 for 2 days with a minimum of four exchanges.  
For vasculature identification, brain samples were incubated with a 1:200 dilution of an 
anti-CD31 rabbit primary Ab (Abcam ab28364) and a 1:200 dilution of an AlexaFlor 594-
conjugated anti-rabbit donkey secondary Ab (Jackson ImmunoResearch 711-585-152) 
with 0.02% NaN3 in PBST for 7 days each with shaking to visualize vasculature. Draq5 
nuclear stain, as above, was added to secondary Ab cocktail. Immunostains were replaced 
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every one-two days with fresh cocktail, and tissues were washed for two days with a 
minimum of four exchanges in PBST with 0.02% NaN3 between stains and after final stain. 
Samples were incubated in RIMS (prepared with Histodenz, Sigma-Aldrich, RI = 1.46) 
with gentle agitation for one day. Glass slides were prepared with 1 mm iSpacers (SunJin 
Lab Co.). Samples were placed inside the spacer, followed by slight overfill of fresh RIMS, 
and a coverslip.  
Z-stacks were acquired with a Zeiss LSM 710 confocal microscope using an Achroplan 20 
/ 0.5 NA water objective with ~40-50% overlap. Linear laser power z-correction was 
applied in Zen software (Zeiss) to ensure uniform signal intensity throughout the sample, 
as even cleared tissue will scatter at depth. For comparative analysis between samples, all 
laser and gain settings were set at the beginning of imaging and were unchanged. Image 
analysis was performed with Imaris (Bitplane). 
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Chapter III 
INVESTIGATION OF TARGETED, SINGLE-AGENT  
THERAPEUTIC NANOPARTICLES IN MOUSE MODELS 
 OF BREAST CANCER BRAIN METASTASIS† 
†Excerpts from this chapter are reprinted from Wyatt EA, Davis ME (2018) Method of establishing breast 
cancer brain metastases affects brain uptake of targeted, therapeutic nanoparticles. Bioengineering and 
Translational Medicine 1–8 with permissions from Bioeng Transl Med. 
3.1 Introduction 
3.1.1 Intracellular trafficking at the BBB  
Of the many strategies to increase brain penetration of systemic therapeutics, 
perhaps one of the most promising is the use of receptor-mediated transcytosis (RMT) 
(1,2). Transferrin receptor (TfR) has been actively explored for RMT across the BBB, due 
to its high expression on BBB endothelium (3). In particular, anti-TfR antibodies (Abs) 
have garnered the most interest because of their ability to bind TfR with high affinity 
without interfering with endogenous transferrin (Tf) (4,5). Results from initial studies 
suggested that reducing the affinity of anti-TfR Abs to TfR maximizes their uptake into the 
brain parenchyma (6). Further investigation revealed that affinity influences intracellular 
trafficking; high-affinity anti-TfR Abs are trafficked to the lysosome, while lower-affinity 
variants are more capable of transcytosis (7). Recently, it has been shown that bivalent 
Ab:TfR binding leads to lysosomal sorting, whereas monovalent binding facilitates 
transcytosis (8). In addition to affinity and valency, in vitro results suggest that pH-
sensitivity of TfR binding also affects trafficking of anti-TfR Abs; an Ab with reduced 
  
66 
affinity at endosomal pH 5.5 showed a greater ability to transcytose than pH-independent 
Abs of comparable affinities at extracellular pH 7.4 (9). However, despite a more detailed 
understanding of the properties that promote transcytosis, several challenges exist in 
translating anti-TfR Abs into the clinic, including the need to: (i) dose very high quantities 
(5), (ii) mitigate effector-function driven safety concerns (10) and (iii) develop species-
specific Abs (11). 
Motivated by the results from anti-TfR Ab trafficking at the BBB, we began to 
investigate how fundamental properties of TfR-targeted nanoparticles affect their 
transcytosis capacity (12). Targeted nanoparticles were chosen for their ability to deliver 
large quantities and a variety of drugs to specific tissues at well-controlled release rates 
(13). In analogy to the results obtained with anti-TfR Abs, Tf-coated gold nanoparticles 
(AuNPs) with reduced avidity to TfR demonstrated the greatest ability to cross the BBB 
(12). Despite showing promise, questions regarding the need for very high systemic dosing 
to achieve sufficient brain accumulation led to alternative nanoparticle designs. Recently, 
an acid-cleavable targeting strategy was incorporated into nanoparticles to increase the 
ability of high-avidity nanoparticles to enter the brain (14). With this design, nanoparticles 
can bind TfR with high avidity on the blood side of the BBB to enable practical, systemic 
dosing, but shed the targeting ligands upon acidification during transcytosis (15), allowing 
free diffusion into the parenchyma (Fig. 3.1). Incorporation of an acid-cleavable linkage 
between Tf and the nanoparticle core increased brain uptake of high-avidity Tf-coated 
AuNPs nearly 3-fold (14). In contrast, no improvement was observed with high-affinity 
anti-TfR-coated AuNPs with the cleavable linker, consistent with their trafficking to the 
  
67 
lysosome. These results suggest that intracellular trafficking may also be affected by the 
particular targeting ligand. 
 
Fig. 3.1. Scheme of acid-cleavable targeting strategy. Following endocytosis, rapid 
acidification of endosome triggers separation of Tf ligands from the nanoparticle core, 
allowing free diffusion of the nanoparticle into the brain parenchyma after transcytosis. 
3.1.2 Investigation of TfR-targeted, therapeutic nanoparticles in models of 
breast cancer brain metastasis 
 
Here, we determine whether nanoparticles can be prepared to deliver therapeutic 
quantities of drug across the BBB. We focused on HER2-positive breast cancer brain 
metastasis because of the inadequate drug concentrations achieved in these tumors in the 
clinical setting. Although a number of preclinical models for this disease have emerged in 
the literature, the effect of the method used to establish metastatic brain tumors on 
therapeutic brain penetration has not been examined. To address these questions, we 
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adapted a targeted nanoparticle delivery system for camptothecin (CPT) previously 
developed in our lab for its use at the BBB (16, 17). Tf was attached to nanoparticles 
consisting of a mucic acid polymer (MAP) conjugate of CPT (MAP-CPT) through a pH-
dependent, boronic acid-diol complexation to form TfR-targeted MAP-CPT nanoparticles 
(Fig. 3.2). We investigated antitumor efficacy and brain uptake of these nanoparticles in 
two types of models from the literature, as well as a new, third model we developed that 
more fully mimics the metastasis process in patients. We found that this targeted 
nanoparticle delivery system can be used to deliver CPT to HER2-positive breast cancer 
brain metastases. Importantly, we also observed significant differences in efficacy as well 
as brain penetration of both TfR-targeted and non-targeted therapeutics between the 
models, showing that the method of establishing brain metastases can affect brain uptake 
of therapeutic agents. 
 
Fig. 3.2. Preparation of TfR-targeted and non-targeted MAP-CPT nanoparticles and pH-
dependence of nitroPBA-diol complex. x ~ 82 for 3.4kDa PEG; y ~ 20 for material used in 
this study; z ~ 120 for 5kDa PEG. 
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3.2 Results 
3.2.1 Synthesis and characterization of TfR-targeted and non-targeted MAP-
CPT nanoparticles 
 
MAP-CPT nanoparticles were chosen for this study because they retained the 
optimal design parameters identified in our previous AuNP formulations, including a sub-
100-nm diameter and near-neutral zeta potential (12). It has also been shown that these 
characteristics facilitate the diffusion of nanoparticles through brain tissue (18). The ketal 
linker previously investigated as the acid-cleavable moiety between the Tf and the 
nanoparticle did not provide optimal cleavage kinetics to remove all surface Tf during 
transcytosis (14). The MAP delivery system allows for assembly of TfR-targeted 
nanoparticles using an improved acid-cleavable chemistry (Fig. 3.2), as discussed below. 
Furthermore, MAP-CPT nanoparticles targeted with an antibody have already been used 
to effectively treat breast cancer xenografts in mice (17). 
MAP-CPT conjugate was synthesized in a similar manner to that previously 
described (Fig. 3.3) (16). Properties of the material used in this study are provided in Table 
3.1. MAP-CPT conjugate was dialyzed against water to promote formation of nanoparticles 
with hydrophobic CPT molecules preferentially clustered in the core and vicinal diols on 
the surface (Fig. 3.2). 
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Fig. 3.3. Synthesis of MAP polymer followed by conjugation of CPT to prepare MAP-CPT 
conjugate. x ~ 82 for 3.4kDa PEG; y ~ 20 for material used in this study. 
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Table 3.1. Properties of MAP polymer and MAP-CPT polymer-drug conjugate. *MW, 
molecular weight determined as (Mw + Mn)/2; Mw, weight average molecular weight; Mn, 
number average molecular weight. †Polydispersity determined as Mw /Mn. 
The boronic acid derivative, 3-carboxy-5-nitrophenyl boronic acid (nitroPBA), was 
added to 5-kDa polyethylene glycol (PEG), followed by conjugation of the polymer to 
human holo-Tf (Fig. 3.4A). A non-targeted analog was prepared using methoxy-terminated 
5-kDa PEG (Fig. 3.4B). NitroPBA was chosen because it forms a boronic acid ester with 
the MAP-CPT diols and has a pKa of 6.8 (16). The nearly instantaneous (relative to the 
timeframe of BBB transcytosis) dissociation of Tf-PEG-nitroPBA from the nanoparticle 
occurs at pH < 6.8, to provide ligand detachment during transcytosis. 
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Fig. 3.4. Synthesis of nitroPBA conjugates. (A) Tf-PEG-nitroPBA. (B) OMe-PEG-
nitroPBA. z ~ 120 for 5kDa PEG. 
To prepare the TfR-targeted and non-targeted MAP-CPT nanoparticles, either Tf-
PEG-nitroPBA or OMe-PEG-nitroPBA was added to the nanoparticles at 20 molar excess 
(Fig. 3.2). All nanoparticle formulations had diameters near 40 nm, as measured by 
dynamic light scattering, and near-neutral zeta potentials when measured in pH 7.4 buffer 
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(Table 3.2). The moderate increase in TfR-targeted nanoparticle size when formulated into 
pH 5.5 buffer is consistent with slight steric destabilization following dissociation of Tf-
PEG-nitroPBA conjugates from the nanoparticle surface diols at acidic pH. Importantly, 
no diameter increase was observed for TfR-targeted nanoparticles after 24 h, indicating the 
multi-PEGylated Tfs in the crude Tf-PEG-nitroPBA mixture were not causing crosslinking 
between nanoparticles (Fig. 3.5). 
 
Table 3.2. Nanoparticle formulations and characteristics. Data shown for hydrodynamic 
diameter and zeta potential are the average of 5 measurements ±1 SD. 
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Fig. 3.5. TfR-targeted MAP-CPT nanoparticle diameter over time. No aggregation or 
increase in size was evident in the sample after 24 h, indicating the nanoparticles were not 
crosslinking due to introduction of multiple nitroPBA-PEG groups per Tf. Error bars 
indicate one standard deviation from the mean. Data shown are the average of 5 
measurements ±1 SD. 
3.2.2 Specific binding of TfR allows targeted nanoparticles to cross an in vitro 
model of the BBB 
 
To perform an initial screen of transcytosis capacity, we used the bEnd.3 
immortalized mouse brain endothelial cell line in an established in vitro model of the BBB 
(19). Nanoparticles were added to the apical compartment of bEnd.3-coated transwells in 
serum-free DMEM and allowed to cross the model BBB for 8 h, after which the full volume 
of the basal compartment was removed and CPT content measured using HPLC. 
After 8 h, TfR-targeted MAP-CPT nanoparticles showed a significantly increased 
capacity to cross the bEnd.3 cells compared to non-targeted nanoparticles (Fig. 3.6). In 
addition, TfR-targeted nanoparticles showed a decreased ability to cross the model BBB 
when coincubated with serum concentrations of Tf, indicating TfR binding is essential to 
crossing. Interestingly, when coincubated with an equimolar amount of high affinity anti-
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TfR Abs, TfR-targeted nanoparticles also revealed a decreased ability to cross the 
transwells, consistent with previous reports of high-affinity Ab:TfR interactions leading to 
lysosomal trafficking (7). 
 
Fig. 3.6. Apical to basal transport of non-targeted and TfR-targeted MAP-CPT 
nanoparticles in model BBB. TfR-targeted (blue) and non-targeted (orange) nanoparticles 
were added to apical wells in either serum-free DMEM (DMEM), or in the presence of 
either 2.5 mg/mL Tf (DMEM + Tf) or equimolar high-affinity anti-TfR Ab (DMEM + Ab). 
Data shown are the average of 4 wells for each group. Error bars indicate SE. 
3.2.3 Brain tumors show significant delay in growth with TfR-targeted 
nanoparticles, but their response differs when established by different 
methods 
  
We compared the efficacy of TfR-targeted MAP-CPT nanoparticles, non-targeted 
MAP-CPT nanoparticles and CPT on the growth of BT474-Gluc brain metastatic tumors 
in Rag2-/-;Il2rg-/- mice established by IC, ICD and IV methods (Fig. 3.7). As detailed in 
Chapter II, this cell line was engineered to express Gaussia luciferase (Gluc) that can be 
used as a surrogate for tumor burden (20). Additionally, Rag2-/-;Il2rg-/- mice were chosen 
because they have shown the ability to allow multi-organ metastatic spread of HER2-
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positive breast cancer cell lines injected IV (21). After IC, ICD or IV injection of BT474-
Gluc cells, formation of brain metastatic tumors was monitored by MRI. A total of six mice 
were used for each treatment group per model, and treatment was initiated when tumors 
reached 2 mm3 in volume. The different formulations were systemically administered by 
lateral tail vein injection once per week for 4 weeks at a dose of 4 mg/kg (CPT basis). Brain 
tumor volume was measured weekly by MRI. Blood Gluc activity was measured in 
addition only for the IC model, due to substantial extracranial tumor burden in the ICD and 
IV models. 
 
Fig. 3.7. Detailed illustration of intracranial (A), intracardiac (B), and intravenous (C) 
breast cancer brain metastasis models, and timelines for efficacy study. Numbers below 
timeline indicate mean (range) time in months to establishment of visible brain metastases 
(BM; ~0.2 mm3 in volume) by MRI. Thick arrows denote treatment schedule for the study, 
with 4 weekly doses administered once tumors reached ~2 mm3 in volume. 
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TfR-targeted MAP-CPT nanoparticles significantly delayed brain metastatic tumor 
growth compared to saline in mice bearing IC-established brain tumors, resulting in an 8.4-
fold decrease in mean tumor volume by the end of the study (Fig. 3.8A and Table 3.3). 
However, treatment with non-targeted MAP-CPT nanoparticles or CPT also led to 
substantial tumor growth inhibition (3.5- or 2.6-fold reduction in mean final tumor volume, 
respectively), supporting the hypothesis that artificial transport pathways may be 
introduced following IC tumor establishment. The blood Gluc activity for each treatment 
group correlated well with tumor volume as measured by MRI (Fig. 3.9). Individual 
antitumor data are provided in Fig. 3.10. 
In contrast to results from the IC model, only treatment with TfR-targeted MAP-
CPT nanoparticles resulted in substantial tumor growth delay compared to saline when 
tumors were established by ICD injection (2.6-fold decrease in mean tumor volume; Fig. 
3.8B and Table 3.4). Interestingly, we observed a modest response with CPT treatment, 
but not with non-targeted MAP-CPT nanoparticles (although this difference was not 
significant).  
Similar to the ICD model, with IV-established brain tumors, TfR-targeted MAP-
CPT nanoparticles markedly slowed tumor growth compared to saline (2.5-fold decrease 
in mean tumor volume; Fig. 3.8C and Table 3.5). Notably, no tumor growth inhibition was 
observed with CPT or non-targeted MAP-CPT nanoparticles compared to saline in this 
model, more closely replicating the clinical situation. 
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Fig. 3.8. Brain tumors established using different methods show differential response to 
therapeutics. Tumor growth curves of BT474-Gluc metastatic brain tumors treated with 
CPT (orange, 4 mg/kg), non-targeted MAP-CPT nanoparticles (gray, 4 mg CPT/kg), and 
TfR-targeted MAP-CPT nanoparticles (blue, 4 mg CPT/kg) compared to saline (black) 
when established by IC (A), ICD (B), and IV injection (C). Data shown are the average of 
6 mice per treatment group. Error bars indicate SE. P values for pairwise comparisons are 
provided in Tables 3.3 to 3.5. 
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Fig. 3.9. Blood Gluc activity of IC-established tumors is correlated with tumor volume, as 
measured by MRI, for each treatment group. Blood Gluc activity is plotted against tumor 
volume for saline (black), CPT (orange), non-targeted MAP-CPT nanoparticle (gray), and 
TfR-targeted MAP-CPT nanoparticle (blue) treatment groups. Linear regression was 
performed using MATLAB. 
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Fig. 3.10. Individual tumor growth curves of BT474-Gluc metastatic brain tumors treated 
with CPT (orange, 4 mg/kg), non-targeted MAP-CPT nanoparticles (gray, 4 mg CPT/kg), 
and TfR-targeted MAP-CPT nanoparticles (blue, 4 mg CPT/kg) compared to saline (black) 
when established by IC (A), ICD (B), and IV injection (C). 
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Table 3.3. Antitumor efficacy in Rag2-/-;Il2rg-/- mice bearing human BT474-Gluc breast 
cancer metastatic brain tumors established by IC injection. Data provided are mean and 
median tumor volumes at the end of the study. P values were calculated using the 
Wilcoxon-Mann-Whitney test. 
 
 
Table 3.4. Antitumor efficacy in Rag2-/-;Il2rg-/- mice bearing human BT474-Gluc breast 
cancer metastatic brain tumors established by ICD injection. Data provided are mean and 
median tumor volumes at the end of the study. P values were calculated using the 
Wilcoxon-Mann-Whitney test. 
 
 
Table 3.5. Antitumor efficacy in Rag2-/-;Il2rg-/- mice bearing human BT474-Gluc breast 
cancer metastatic brain tumors established by IV injection. Data provided are mean and 
median tumor volumes at the end of the study. P values were calculated using the 
Wilcoxon-Mann-Whitney test. 
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3.2.4 Brain uptake of therapeutics differs in tumor, but not healthy tissue 
between models 
To ascertain whether differences in brain penetration of the therapeutics might 
explain the discordance in efficacy between brain metastasis models, we systemically 
administered an additional dose of each treatment at the end of the efficacy study. After 24 
h, mice were anesthetized and perfused with PBS to clear any remaining nanoparticles or 
free drug from the bloodstream. Drug uptake into tumor and healthy brain tissue was 
quantified by HPLC as previously described (17). 
Tumor tissue collected from IC-established, but not from ICD- and IV-established 
brain tumors showed significant accumulation of CPT and non-targeted MAP-CPT 
nanoparticles, consistent with the hypothesis that the barrier in IC-established tumors may 
be more permeable to therapeutics than what is observed in patients with HER2-positive 
disease (Fig. 3.11A). In addition, cells isolated from BT474-Gluc tumors from all three 
models as well as the respective parental cells had comparable sensitivities to CPT in vitro 
(Fig. 3.12), ruling out permanent, model-specific drug sensitivity as the origin for anti-
tumor differences. Thus, these data strongly implicate BBB/BTB permeability to the 
therapeutic agents as a mediator of the differential treatment response between the models. 
Importantly, TfR-targeted MAP-CPT nanoparticles showed the highest 
accumulation in IC-, ICD- and IV-established brain tumor tissue. In addition, TfR-targeted 
nanoparticles demonstrated increased penetration into healthy brain tissue relative to free 
drug and non-targeted nanoparticles in all three models (Fig. 3.11B). As with the antitumor 
efficacy data, these results further indicate the potential of the TfR-targeted nanoparticle 
delivery system. 
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Fig. 3.11. Brain uptake of therapeutics is model-dependent in tumor, but not healthy tissue. 
(A) Brain uptake in BT474-Gluc tumor tissue as calculated by percent injected dose per g 
of tissue for different treatments. (B) Percent injected dose in healthy brain tissue. Brain 
uptake was determined 24 h after a 4 mg/kg dose (CPT basis). Data shown are the average 
of 4 mice per treatment group. Error bars indicate SE. ND, not detectable. P values for 
pairwise comparisons are provided in Tables 3.6 and 3.7.  
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Table 3.6. P values for pairwise comparisons of uptake of therapeutics in brain metastases. 
Values were calculated using the Wilcoxon-Mann-Whitney test. *CPT, IC model; †Non-
targeted MAP-CPT nanoparticles, IC model; ‡TfR-targeted MAP-CPT nanoparticles, IC 
model; §CPT, ICD model; ¶Non-targeted MAP-CPT nanoparticles, ICD model; #TfR-
targeted MAP-CPT nanoparticles, ICD model; ||CPT, IV model; **Non-targeted MAP-CPT 
nanoparticles, IV model; ††TfR-targeted MAP-CPT nanoparticles, IV model. 
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Table 3.7. P values for pairwise comparisons of uptake of therapeutics in healthy brain 
tissue. Values were calculated using the Wilcoxon-Mann-Whitney test. *CPT, IC model; 
†Non-targeted MAP-CPT nanoparticles, IC model; ‡TfR-targeted MAP-CPT 
nanoparticles, IC model; §CPT, ICD model; ¶Non-targeted MAP-CPT nanoparticles, ICD 
model; #TfR-targeted MAP-CPT nanoparticles, ICD model; ||CPT, IV model; **Non-
targeted MAP-CPT nanoparticles, IV model; ††TfR-targeted MAP-CPT nanoparticles, IV 
model. 
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Fig. 3.12. BT474-Gluc cells isolated from brain tumors following IC- (circle), ICD- 
(square), and IV-establishment (triangle) as well as parental cells (solid circle) are similarly 
sensitive to CPT. Data shown are the average of 4 dose-response curves for each cell line. 
Error bars indicate SE. 
3.3 Discussion 
 
Here, we focused on understanding whether two types of breast cancer brain 
metastasis mouse models from the literature as well as a third, new model created in this 
study provide impaired drug delivery to brain metastases like what is observed for patients 
with HER2-positive, metastatic breast cancer. In patients, non-BBB-permeable agents are 
unable to accumulate in brain metastases in pharmacologically active amounts. However, 
we did not observe this same delivery limitation in the IC model. Our results show that a 
non-BBB-penetrant small molecule (CPT) and a non-targeted nanoparticle therapeutic (ca. 
30-40 nm diameter) can elicit a significant antitumor response as well as accumulate in 
high amounts in IC-established brain tumors. Although this model may be useful for 
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studying basic biological mechanisms, our findings suggest this model must be used with 
caution for translational research with diseases where a non-permissive BBB is clinically 
relevant. 
In contrast to the IC model, both the ICD and IV models provide for a more intact 
BBB/BTB. Our results indicate that the ICD model may allow for a slightly increased 
permeability to small molecule drugs, but not to larger nanoparticle entities when compared 
to the IV model. Consistent with a modest uptake in healthy brain tissue, it is possible that 
the high number of microscopic tumor foci commonly observed throughout the brain 
following ICD injection may contribute to a slight net increase in parenchymal penetration 
as a whole. Nevertheless, this effect was minimal. Most importantly, our data show that 
the method of establishing brain tumors can dramatically affect the efficacy of therapeutics 
and their brain penetration. Thus, if the experimenter is interested in transport properties 
of a given therapeutic, then the use of the IC model is questionable.     
Additionally, we show that TfR-targeted nanoparticles are capable of delivering a 
small molecule chemotherapeutic, CPT, to HER2-positive breast cancer brain metastases. 
We observed that TfR-targeted MAP-CPT nanoparticles significantly slowed tumor 
growth in the brain and demonstrated increased accumulation in brain metastases relative 
to free drug and non-targeted nanoparticles. The specific example of assembling a TfR-
targeted nanoparticle system for CPT was selected to test the delivery strategy. CPT is not 
a particularly good drug for use with BT474 cells (relative to other breast cancer cell lines 
(16)). Thus, it is encouraging to observe tumor growth delay when delivering CPT via 
targeted nanoparticles to the BT474-Gluc brain metastases. It is expected that TfR-targeted 
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nanoparticles delivering therapeutic agents with greater potency will reveal even more 
significant tumor size reductions.  
Further, it is important to note that TfR-targeted nanoparticles accumulated in 
significant amounts in healthy brain tissue when compared to free drug and non-targeted 
nanoparticles in all three models. This observed whole-brain penetration has implications 
for the selection of therapeutics that should be incorporated into this delivery system and 
of target diseases. In the case of brain cancers, the ability to penetrate not only tumor tissue, 
but also healthy tissue could be advantageous in accessing micrometastases or fingers of 
glioma tumors that are frequently the reason for treatment failure. At the same time, the 
broad nanoparticle accumulation in the brain will require careful thought as to which drugs 
are used in this application, due to potential toxicity issues. For other brain diseases where 
whole-brain therapeutic exposure is highly desired, such as neurodegenerative diseases, 
this targeted nanoparticle system may offer a compelling approach to delivering 
therapeutics across an intact BBB. 
3.4 Conclusions 
 
Here, we show that the method used to establish breast cancer brain metastases can 
affect efficacy and brain uptake of therapeutic agents. We observed a significant antitumor 
response as well as brain tumor accumulation of a non-BBB-penetrant small molecule and 
a non-targeted nanoparticle therapeutic in tumors that were formed by IC injection of 
human breast cancer cells. In contrast, both ICD and IV injection of the cancer cells 
provided for a more clinically relevant, impermeable BBB/BTB to non-penetrant agents. 
Additionally, we show that TfR-targeted MAP-CPT nanoparticles can accumulate in brain 
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metastases in greater amounts and lead to improved antitumor activity compared to free 
drug and non-targeted MAP-CPT nanoparticles. Furthermore, TfR-targeted nanoparticles 
showed an increased ability to cross an intact BBB, resulting in whole-brain therapeutic 
accumulation. 
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3.5 Materials and methods 
Synthesis of MAP-CPT Conjugate. 1H NMR spectra were acquired on a Varian 600 MHz 
spectrometer (Inova). Electrospray ionization (ESI) masses of small molecules were acquired 
on a Finnigan LCQ ion trap mass spectrometer. Matrix-assisted laser desorption/ionization-
time-of-flight (MALDI-TOF) mass spectra for polymers were acquired on an Applied 
Biosystems Voyager DE-PRO. 
Synthesis of Mucic Acid Dimethyl Ester. Methanol (360 mL) was added to mucic acid (15 
g, 1 equiv, Alfa Aesar) in a 500 mL round-bottomed flask. To this was added concentrated 
sulfuric acid (1.2 mL, 0.3 equiv). The suspension was stirred and refluxed at 85 ºC overnight. 
The mixture was cooled to room temperature and filtered through a Buchner funnel using 
Whatman Grade 5 filter paper. The solid was washed with methanol (600 mL), and 
recrystallized with a mixture of methanol (240 mL) and triethylamine (1.5 mL) at 85 ºC for 
1 h. The mixture was again cooled to room temperature and filtered. The solid was washed 
with methanol (600 mL), and dried under vacuum at 75 ºC overnight to yield mucic acid 
dimethyl ester (14.2 g) as a white solid. 1H NMR (600 MHz, DMSO-d6): 4.91 (d, 2H), 4.80 
(q, 2H), 4.28 (d, 2H), 3.78 (q, 2H), 3.63 (s, 6H). ESI/MS: 261.0 [M+Na]+. 
Synthesis of N-Boc-Protected Mucic Acid Ethylenediamine. Methanol (225 mL) was 
added to mucic acid dimethyl ester (14.2 g, 1 equiv) in a 500 mL round-bottomed flask. To 
this was added triethylamine (21.7 mL, 2.6 equiv), and the mixture was stirred and refluxed 
at 85 ºC for 30 min, forming a yellow suspension. N-Boc-ethylenediamine (24.6 mL, 2.6 
equiv, AK Scientific) in methanol (55 mL) was added, and the reaction was stirred and 
refluxed at 85 ºC overnight. The mixture was cooled to room temperature, and filtered 
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through a Buchner funnel using Whatman Grade 5 filter paper. The solid was washed with 
methanol (750 mL), and recrystallized with methanol (350 mL) at 85 ºC for 1.5 h. The 
mixture was again cooled to room temperature and filtered. The solid was washed with 
methanol (750 mL), and dried under vacuum at 75 ºC overnight to yield N-Boc-protected 
mucic acid ethylenediamine (19.2 g) as a white solid. 1H NMR (600 MHz, DMSO-d6): 7.71 
(t, 2H), 6.81 (t, 2H), 5.13 (d, 2H), 4.35 (q, 2H), 4.09 (d, 2H), 3.77 (q, 2H), 3.12 (m, 4H), 2.98 
(m, 4H), 1.36 (s, 18). ESI/MS: 517.1 [M+Na]+. 
Synthesis of Mucic Acid Ethylenediamine. N N-Boc-protected mucic acid ethylenediamine 
(19.2 g) in a 500 mL round-bottomed flask was placed in a water bath. 3 N hydrochloric acid 
in methanol (325 mL) was added, and the reaction flask was sealed and vented with a needle. 
The suspension was stirred at 25 ºC for 8 h. The slurry was filtered through a glass frit with 
a fine grain, and washed with methanol (900 mL) until the filtrate pH was close to neutral. 
The solid was dried under vacuum at 80 ºC overnight to yield mucic acid ethylenediamine 
(11.5 g) as a white solid. 1H NMR (600 MHz, DMSO-d6): 7.97–7.84 (m, 8H), 5.30 (d, 2H), 
4.58 (d, 2H), 4.16 (d, 2H), 3.82 (m, 2H), 3.39–3.32 (m, 4H), 2.85 (m, 4H). ESI/MS: 295.0 
[M+H]+. 
Synthesis of Mucic Acid Di(Asp(OBzl)-Boc). Mucic acid ethylenediamine (3 g, 1 equiv) 
was dissolved in 30 mL DMSO in a 250 mL round-bottomed flask. To this was added Boc-
Asp(OBzl)-OSu (10.3 g, 3 equiv, Bachem) in acetonitrile (80 mL) and pyridine (3.2 mL, 5 
equiv). The reaction was stirred and refluxed at 60 ºC overnight. The mixture was cooled to 
room temperature, and acetonitrile was removed by rotary evaporation. The solution was 
precipitated by addition of nanopure water, and the precipitate was recrystallized with 
nanopure water (100 mL) at 85 ºC for 1 h. The mixture was cooled to room temperature, 
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filtered through a glass frit with a fine grain, and washed with nanopure water (200 mL). The 
recrystallization procedure was repeated with acetonitrile. The solid was dried under vacuum 
at 50 ºC overnight to yield mucic acid di(Asp(OBzl)-Boc) (2.1 g) as a white solid. 1H NMR 
(600 MHz, DMSO-d6): 7.94 (t, 2H), 7.76 (t, 2H), 7.37–7.31 (m, 10H), 7.06 (d, 2H), 5.13–
5.08 (m, 6H), 4.37–4.32 (d, 2H), 4.30–4.28 (d, 2H), 4.14–4.12 (d, 2H), 3.81–3.79 (d, 2H), 
3.18–3.09 (m, 8H), 2.79–2.57 (m, 4H), 1.38 (s, 18H). ESI/MS: 905.0 [M+H]+. 
Synthesis of Mucic Acid Di(Asp(OBzl)-amine). Dichloromethane (18 mL) was added to 
mucic acid di(Asp(OBzl)-Boc) (2.1 g, 1 equiv) in a 50 mL round-bottomed flask vented with 
argon. The flask was cooled to 0 ºC in an ice bath, and trifluoroacetic acid (6 mL, 36 equiv) 
was added dropwise. The reaction was stirred for 8 h under argon, slowly equilibrating to 
room temperature. Solvent was removed by rotary evaporation. The solid was dissolved in 
dichloromethane (30 mL) and dried by rotary evaporation twice more, and then recrystallized 
with tetrahydrofuran (30 mL) at 55 ºC for 1 h. The mixture was cooled to room temperature 
and filtered through a glass frit with a fine grain. The solid was washed with tetrahydrofuran 
(100 mL), and dried under vacuum at 50 ºC overnight to yield mucic acid di(Asp(OBzl)-
amine) (1.4 g) as a white solid. 1H NMR (600 MHz, DMSO-d6): 8.46 (t, 2H), 8.21 (s, 6H), 
7.80 (t, 2H), 7.39–7.35 (m, 10H), 5.19–5.16 (t, 2H), 5.13 (s, 4H), 4.41 (s, 2H), 4.15–4.13 (d, 
2H), 4.06–4.04 (d, 2H), 3.83 (s, 2H), 3.22–3.16 (m, 8H), 3.02–2.83 (m, 4H). ESI/MS: 705.3 
[M+H]+. 
Synthesis of Mucic Acid Di(Asp-amine). Methanol (50 mL) was added to mucic acid 
di(Asp(OBzl)-amine) (1.4 g, 1 equiv) and 20% (w) palladium hydroxide on carbon (568 
mg, 10 equiv) in a 100 mL round-bottomed flask. The reaction flask was sealed and vented 
with argon for 30 min. Hydrogen gas was added by a double-layered balloon, and the 
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reaction was stirred for 24 h at room temperature. Catalyst was separated by centrifugation 
at 3220 g for 15 min, and the solvent removed by rotary evaporation. The solid was 
reconstituted in nanopure water, and the solution was filtered through a 0.2 µm Supor 
membrane Acrodisc syringe filter (Pall) and lyophilized to yield mucic acid di(Asp-amine) 
(1.1 g) as a white solid. 1H NMR (600 MHz, DMSO-d6): 8.39 (t, 2H), 8.18 (broad, 6H), 
7.77 (t, 2H), 5.18 (t, 2H), 4.46 (s, 2H), 4.12 (s, 2H), 3.96–3.94 (m, 2H), 3.79 (s, 2H), 3.21–
3.11 (m, 8H), 2.84–2.65 (m, 4H). ESI/MS: 525.2 [M+H]+. The product was stored under 
argon at -20 ºC. 
Synthesis of Mucic Acid Polymer (MAP). Mucic acid di(Asp-amine) (220 mg, 1 equiv) 
and di(succinimidyl proprionate)-PEG (3.4 kDa, 1 g, 1 equiv, JenKem) were equilibrated 
to room temperature for 1 h, then added to an oven-dried 10 mL round-bottomed flask. The 
reaction flask was sealed, and the two solids were dried under vacuum for 4 h. Anhydrous 
dimethyl sulfoxide (7 mL) was added under argon to dissolve the two solids. To this was 
added anhydrous N,N-diisopropylethylamine (205 µL, 4 equiv) dried over molecular 
sieves, and the solution was stirred under argon at room temperature for 42 h. The solution 
was dialyzed against dimethyl sulfoxide and nanopure water using a 10 kDa MWCO 
Spectra/Por 7 membrane (Spectrum), filtered through a 0.2 µm Supor membrane Acrodisc 
syringe filter (Pall) and lyophilized to yield MAP (983 mg) as a white, sponge-like solid. 
1H NMR (600 MHz, DMSO-d6): 8.11 (d, 1H), 8.08 (d, 1H), 7.83 (t, 1H), 7.79 (t, 1H), 7.73 
(t, 2H), 4.49 (td, 2H), 4.14 (d, 2H), 3.69 (ddt, 2H), 3.59 (t, 4.3H), 3.53–3.43 (s - PEG), 
3.18–3.07 (m, 8H), 2.61–2.43 (m, 4H), 2.38 (t, 4.3H). 
Determination of MAP Molecular Weight. Polymer molecular weight was determined on 
a gel permeation chromatography (GPC) system equipped with an Agilent 1100 HPLC 
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with binary pump and injector with 2 size exclusion columns in series (PL aquagel-OH 40 
8 µm, Agilent) connected to Wyatt DAWN HELEOS light scattering and Wyatt Optilab 
rEX refractive index detectors. MAP was dissolved at six different concentrations in PBS, 
pH 7.4 and directly injected into the refractive index detector at 0.2 mL/min using a syringe 
pump to determine specific refractive increment, dn/dc. Absolute molecular weight was 
determined by injecting 100 µL of MAP dissolved at 4 mg/mL in PBS, pH 7.4 onto the 
column. PBS was used as the eluent at a flow rate of 0.7 mL/min, and the detected polymer 
peak was analyzed using ASTRA V Software. 
Synthesis of MAP-CPT Conjugate. Anhydrous dimethyl sulfoxide (10 mL) was added 
under argon to dissolve MAP (200 mg, 1 equiv) in a 25 mL round-bottomed flask. To this 
was added EDC (83 mg, 4 equiv) and NHS (32 mg, 3 equiv) dissolved in anhydrous 
dimethyl sulfoxide (3 mL), followed by 20-O-Glycincamptothecin trifluoroacetic acid salt 
(CPT-gly.TFA, 170 mg, 3 equiv) dissolved in dimethyl sulfoxide (3 mL) and anhydrous 
N,N-diisopropylethylamine (56 µL) dried over molecular sieves. The reaction was stirred 
under argon at room temperature overnight. The solution was dialyzed against dimethyl 
sulfoxide 3 times and nanopure water 2 times using a 10 kDa MWCO Spectra/Por 7 
membrane (Spectrum). Precipitate was removed by centrifugation at 3220 g for 15 min, 
and the supernatant was filtered through a 0.2 µm Supor membrane Acrodisc syringe filter 
(Pall) to yield MAP-CPT conjugate as self-assembled nanoparticles in solution. A portion 
of this clear yellow solution was lyophilized to determine percent CPT conjugation. The 
remaining product was formulated into 0.9% (w/v) saline and stored at -20 ºC. 
Determination of CPT Content in MAP-CPT. Lyophilized MAP-CPT was dissolved in 
dimethyl sulfoxide at 10 mg/mL, diluted to 0.1 mg/mL with 1 N NaOH, and incubated 
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overnight. Fluorescence was measured at 370/440 nm (ex/em) using a Safire 2 multi-mode 
plate reader (Tecan). A calibration curve of known concentrations of CPT was prepared 
and used to determine the CPT concentration in the mixture. 
Synthesis of CO2H-PEG-nitroPBA and OMe-PEG-nitroPBA.  
Synthesis of 3-acyl chloride-5-nitrophenyl boronic acid. 3-carboxy-5-nitrophenyl boronic 
acid (nitroPBA, 100 mg, 1 equiv, Alfa Aesar) was added to an oven-dried 10 mL round-
bottomed flask. The reaction flask was sealed and vented with argon. Anhydrous 
tetrahydrofuran with BHT inhibitor (4 mL) was added to dissolve the boronic acid, 
followed by anhydrous dimethylformamide (7 µL, 0.2 equiv). The flask was cooled to 0 
ºC in an ice bath, and oxalyl chloride (98 µL, 2.4 equiv) was added dropwise. After addition 
of oxalyl chloride, the ice bath was removed and the reaction was stirred under argon for 2 
hrs. Solvent was evaporated under vacuum to yield 3-acyl chloride-5-nitrophenyl boronic 
acid (108 mg) as a yellow solid. 
Synthesis of CO2H-PEG-nitroPBA and OMe-PEG-nitroPBA. 3-acyl chloride-5-
nitrophenyl boronic acid (46 mg, 2 equiv) was added to an oven-dried 25 mL round-
bottomed flask. The reaction flask was sealed, vented with argon, and cooled to 0 ºC in an 
ice bath. Anhydrous DCM (5 mL) was added to dissolve the boronic acid. Acetic acid-
PEG-amine (5 kDa, 500 mg, 1 equiv, JenKem) was added to a separate oven-dried 10 mL 
round-bottomed flask. The flask was sealed, and vented with argon. To this was added 
anhydrous N,N-diisopropylethylamine (35 µL, 2 equiv) dried over molecular sieves, and 
anhydrous DCM (5 mL) to dissolve the PEG. The PEG solution was added dropwise to the 
boronic acid solution. The reaction flask was left in the ice bath to slowly warm to room 
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temperature, and stirred under argon overnight protected from light. Solvent was removed 
under vacuum, and the solid reconstituted in 0.5 N HCl (5 mL) and stirred for 15 min. The 
solution was filtered through a 0.2 µm Supor membrane Acrodisc syringe filter (Pall) and 
dialyzed against nanopure water until constant pH using a 15 mL Amicon Ultra 3 kDa spin 
filter (EMD Millipore), and lyophilized to yield CO2H-PEG-nitroPBA (465 mg) as a white 
solid. 1H NMR (600 MHz, DMSO-d6): 12.52 (s - COOH, 1H), 8.90 (t, 1H), 8.73 (m, 1H), 
8.69 (m, 1H), 8.65 (m, 1H), 8.61 (s, 2H), 4.00 (s, 2H), 3.53–3.46 (s - PEG). MALDI: 
5496.0.      
A similar procedure was followed using methoxy-PEG-amine (5 kDa, 500 mg, 1 equiv, 
JenKem) to synthesize OMe-PEG-nitroPBA. 1H NMR (600 MHz, DMSO-d6): 8.90 (t, 1H), 
8.72 (m, 1H), 8.69 (m, 1H), 8.64 (m, 1H), 8.60 (s, 2H), 3.54–3.48 (s - PEG), 3.23 (s, 2H). 
MALDI: 5825.4. 
Synthesis of Tf-PEG-nitroPBA. CO2H-PEG-nitroPBA (16 mg, 25 equiv), EDC-HCl (6.1 
mg, 250 equiv), and NHS (5.5 mg, 375 equiv) were dissolved in 0.1 M MES buffer, pH 
6.0 (0.33 mL), and stirred for 15 min at room temperature. The reaction mixture was then 
added to a 0.5 mL Amicon Ultra 3 kDa spin filter (EMD Millipore), and centrifuged to 
isolate the activated nitroPBA-PEG-NHS ester. The ester was added to human holo-Tf (10 
mg, 1 equiv, Sigma) dissolved in 0.1 M PBS, 0.15 M NaCl, pH 7.4 (1 mL). The reaction 
was lightly agitated for 2 h at room temperature, and then dialyzed against 0.1 M PBS, 0.15 
M NaCl, pH 7.4 using 0.5 mL Amicon Ultra 50 kDa spin filters (EMD Millipore) to remove 
excess PEG. A portion of this solution was dialyzed into 10 mM PB, pH 7.4, and 
conjugation was verified by MALDI-TOF (autoflex speed TOF/TOF, Bruker) using a 
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sinapinic acid matrix. MALDI-TOF: 85295.4. The amount of iron loaded to the Tf was 
verified by UV-VIS on a NanoDrop system (Thermo Scientific) using the ratio of 
A465/A280. This ratio was compared to that of the unreacted human holo-Tf, and a value ≥ 
80% of the unreacted ratio confirmed adequate iron retention following synthesis steps. 
The remaining Tf-PEG-nitroPBA was formulated into PBS, pH 7.4, and stored at 4 ºC. 
Preparation of Nanoparticles. Either OMe-PEG-nitroPBA or Tf-PEG-nitroPBA 
conjugates in PBS, pH 7.4 were added at 20x molar excess to MAP-CPT nanoparticles to 
form non-targeted and TfR-targeted MAP-CPT nanoparticles, respectively (20 OMe or Tf 
per particle). The solution was gently mixed by pipette, and allowed to equilibrate for 10 
min. Nanoparticle formulations were filtered using a 0.45 µm PTFE membrane Millex-LH 
syringe filter (EMD Millipore). 
Nanoparticle Characterization. Nanoparticles were characterized using a Brookhaven 
Instruments Corporation (BIC) ZetaPALS. Nanoparticles were diluted in PBS, pH 7.4 or 
PB, pH 5.5, and hydrodynamic diameter was measured by dynamic light scattering (DLS) 
using BIC Particle Sizing Software. Measurements were performed in solutions of different 
pH to allow for characterization under conditions where OMe-PEG-nitroPBA and Tf-PEG-
nitroPBA conjugates would be bound to the vicinal diols on MAP (pH 7.4) and where 
nitroPBA conjugates would dissociate from the diols on MAP (pH 5.5). Particle 
formulations were diluted in 10 mM PB, pH 7.4 or 1 mM KCl, pH 5.5, and zeta potential 
was measured using BIC PALS Zeta Potential Analyzer software with a target residual of 
0.02. Five runs were performed for both the nanoparticle diameter and zeta potential 
measurements. 
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Nanoparticle Transwell Assay. bEnd.3 cells were obtained from ATCC and maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) FBS and 
1% penicillin/streptomycin in a humidified oven at 37 °C with 5% CO2. Media was added 
to apical and basal wells of 12 mm polyester-coated Transwell supports (Corning), and 
allowed to equilibrate overnight at 37 ºC. Cells were added to the apical well at 82,500 
cells/well. Media was replaced in the apical and basal wells every 2 days. Transepithelial 
electrical resistance (TEER) was measured in an Endohm chamber using an EVOM 
resistance meter (World Precision Instruments). Once TEER reached ≥ 30 Ohm∙cm2, 
transcytosis experiments were performed. Prior to introduction, both compartments of the 
Transwell were washed with serum-free DMEM, and allowed to equilibrate for 1 h. 
Nanoparticles were added at 1 µg of CPT/well to the apical well. After 8 h, the entire 
volume was removed from the basal well, and immediately frozen at -80 ºC until time for 
analysis. For the Tf-competition assay, the experiment was performed as described above 
using DMEM + 2.5 mg/mL Tf as the media in both apical and basal wells. For the high 
affinity anti-TfR coincubation assay, the nanoparticles were formulated with an equimolar 
(Tf:Ab) amount of R17217 anti-TfR Ab (Biolegend) in serum-free DMEM and added to 
the apical chamber. 
The amount of CPT in the basal well was determined on an Agilent 1100 HPLC system 
with a reverse phase column (Synergi 4 µm Hydro-RP 80 Å, Phenomenex) connected to a 
fluorescence detector set to 370/440 nm (ex/em). 50% acetonitrile/50% potassium 
phosphate buffer (10 mM, pH 4) was used as the eluent at a flow rate of 0.5 mL/min. To 
cleave CPT from the MAP polymer, 13 µL of 0.1 N NaOH was added to 20 µL sample 
and incubated for 1 h. Then, 20 µL of 0.2 N HCl was added to convert the carboxylate CPT 
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to the lactone form, followed by 30 min incubation. Subsequently, 147 µL methanol was 
added, and the mixture incubated for 2 h at room temperature for protein precipitation. The 
sample was centrifuged at 14000 g for 15 min and supernatant filtered using a 0.45 µm 
PTFE membrane Millex-LH syringe filter (EMD Millipore). CPT content was determined 
by injecting 100 µL of the filtered solution onto the column compared to a calibration curve 
of known concentrations of CPT. Reported values are the average of four wells per group. 
The error shown is standard error of the mean. Pairwise group comparisons testing for 
statistically significant differences were performed using the Wilcoxon-Mann-Whitney test 
in MATLAB. 
Antitumor Efficacy in IC, ICD, and IV Brain Metastasis Models. 
IC, ICD and IV Tumor Models. All animals were treated according to the NIH guidelines 
for animal care and use as approved by the Caltech Institutional Animal Care and Use 
Committee. BT474-Gluc cells, transduced with an expression cassette encoding Gluc and 
CFP separated by an internal ribosomal entry site using a lentiviral vector, were obtained 
from Dr. Jain at Harvard University. BT474-Gluc cells were maintained in RPMI 1640 
supplemented with 10% (v/v) FBS in a humidified oven at 37 °C with 5% CO2. For the IC 
model, 50,000 BT474-Gluc cells in 2 µL RPMI were intracranially injected into the right 
cerebral hemisphere of female Rag2-/-;Il2rg-/- mice (Jackson Laboratory) using a 
stereotaxic apparatus at a rate of 0.1 µL/min. The coordinates for injection were 2 mm 
posterior, 1.5 mm lateral to bregma, and 2.5 mm depth from bregma. For the ICD model, 
100,000 BT474-Gluc cells were suspended in 100 µL of RPMI and slowly injected into 
the left ventricle of female Rag2-/-;Il2rg-/- mice. Injections were performed blind, midway 
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between the sternal notch and top of xyphoid process, and 13% anatomical left of sternum. 
Successful insertion into the left cardiac ventricle was confirmed by a bright red pulse of 
blood in the syringe. For the IV model, 2 M cells were suspended in 150 µL RPMI and 
slowly injected into the lateral tail vein of restrained female Rag2-/-;Il2rg-/- mice. 
Tumor Size Monitoring. For ICD and IV models, formation of BT474-Gluc brain 
metastatic tumors was monitored by MRI on a 11.7-T magnet every third week until 
macroscopic tumors were visible (~0.2 mm3 in volume). Tumor growth was then 
monitored weekly by MRI, as for the IC model. Mice were anaesthetized with 1.5–2% 
(v/v) isoflurane in O2 at a flow rate of 1–1.5 mL/min. T2-weighted 3D RARE images were 
acquired to assess the tumor volume. The image acquisition parameters were as follows: 
echo time: 6.1 ms; repetition time: 250 ms; rapid acquisition relaxation enhanced (RARE) 
factor: 4; number of averages: 4; field of view: 2.0 cm x 1.2 cm x 0.8 cm; matrix: 200 x 
120 x 80 (100 µm isotropic resolution). Tumor volume was determined manually from the 
T2 hyperintense tumor regions of the brain using Fiji software. For the IC model, tumor 
size was also monitored by measuring the activity of secreted Gluc in the blood. 20 µL of 
blood was collected weekly from the saphenous vein, mixed with 5 µL of 50 mM EDTA, 
and immediately frozen at -20 ºC until time for analysis. Blood was transferred to an 
opaque 96-well plate (Nunc), and Gluc activity measured using the Pierce Gaussia 
Luciferase Flash Assay Kit, according to the manufacturer’s protocol. Photon counts were 
acquired for 5 s following addition of coelenterazine using a Safire 2 multi-mode plate 
reader (Tecan). Pairwise group comparisons testing for statistically significant differences 
were performed using the Wilcoxon-Mann-Whitney test in MATLAB. 
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Treatments. Treatment began when brain metastatic tumors reached ~2 mm3, as measured 
by MRI. Mice in each model were randomized into four groups of six mice per group. CPT, 
non-targeted MAP-CPT nanoparticles, and TfR-targeted MAP-CPT nanoparticles were 
freshly prepared. The different formulations were systemically administered by lateral tail 
vein injection once per week for 4 weeks at a dose of 4 mg/kg (CPT basis). Injections were 
standardized to 150 µL per 20 g body weight. CPT is highly insoluble in aqueous solutions; 
therefore, it was dissolved in a solution containing 20% DMSO, 20% PEG 400, 30% 
ethanol, and 30% 10 mM pH 3.5 phosphoric acid. Nanoparticle treatments were prepared 
and administered in PBS, pH 7.4 as previously described. The control treatment was 0.9% 
(w/v) saline. 
No gross signs of toxicity were observed from either the non-targeted or the targeted 
nanoparticles in our study, while animals did have reactions to dosing with the CPT alone. 
These reactions are common and documented in the literature for CPT (23,24). 
Measurement of CPT Concentration in Brain. Eight weeks after the beginning of the 
treatment, four of six mice per treatment group were systemically administered by lateral 
tail vein injection one additional dose at 4 mg/kg (CPT basis). After 24 h, the mice were 
anaesthetized and transcardially perfused with PBS, pH 7.4. Brain tumors were collected 
and sectioned into two approximately equal sized pieces. An equally sized piece of healthy 
brain tissue was collected from the brain region contralateral to the tumor location. One 
piece of the tumor and the healthy tissue were weighed and placed in separate Lysing 
Matrix A tubes containing ¼ inch ceramic spheres (MP Biomedicals) in RIPA buffer (Cell 
Signaling Technologies) at a fixed ratio (w/v). Tissues were homogenized using a 
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FastPrep-24 homogenizer (MP Biomedicals) at a rate of 6 m/s for 30 s. A total of three 
homogenization steps occurred with a 1 min rest on ice between steps. After the final 
homogenization step, samples were rotated for 30 min, then centrifuged at 14000 g for 15 
min at 4 ºC. The supernatant was collected, and immediately frozen at -80 ºC until time for 
analysis. CPT uptake into tumor and healthy brain tissue for each formulation was 
determined by HPLC, as described above. Pairwise group comparisons testing for 
statistically significant differences were performed using the Wilcoxon-Mann-Whitney test 
in MATLAB. 
Brain Metastatic Tumor Cell Isolation and Cytotoxicity Assay. The second piece of 
brain tumor tissue was immediately minced ice cold RPMI, and incubated in RPMI 
supplemented with 10% (v/v) FBS, 1% penicillin/streptomycin and 1 mg/mL 
collagenase/dispase enzyme mix (Roche) at 37 °C for 1 h with shaking. The tissue was 
then centrifuged at 300 g for 5 min, and supernatant removed. The pellet was resuspended 
in RPMI supplemented with 10% (v/v) FBS and 1% penicillin/streptomycin, and the cells 
cultured in a humidified oven at 37 °C with 5% CO2. Media was refreshed after 24 h, and 
every 2 days thereafter. After 1 week, the majority of the cells were BT474-Gluc tumor 
cells, as identified by CFP.  
BT474-Gluc cells dissociated from the brain parenchyma, as well as parental cells, were 
seeded at a density of 3,000 cells/well in 96-well plates. After 24 h, media was removed 
and replaced with fresh media containing different concentrations of CPT. After 72 h, 
BT474-Gluc cell viability was measured using the CellTiter 96 Aqueous One Solution cell 
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proliferation assay (Promega) on an Infinite M200 microplate reader (Tecan), according to 
the manufacturer’s protocol. 
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Chapter IV 
OVERALL SUMMARY AND CONCLUSIONS 
HER2 overexpression is observed in about 25% of human breast cancers, and is 
associated with increased aggressiveness of the tumor as well as poor patient prognosis (1). 
Treatment with HER2-targeted therapeutics such as trastuzumab has improved clinical 
outcomes in these patients, but also unveiled a new challenge to their long term survival – 
brain metastases (2,3). As many as half of patients with HER2-positive, metastatic disease 
will develop brain metastases over the course of their disease (4). Like most brain diseases, 
brain metastases are largely untreatable due to the inability of most therapeutics to cross 
the BBB/BTB from circulation and enter the brain (4,5). Approaches to overcome limited 
drug delivery to the brain have the potential to elicit more durable responses in these 
patients and offer a much needed glimmer of hope for many others suffering from a range 
of brain diseases. 
 One promising strategy to increase brain uptake of therapeutics in circulation is to 
exploit endogenous transport systems at the BBB to shuttle drugs into the brain. Of the 
transport mechanisms at the BBB, only the transcytosis pathway is compatible with 
delivery of a wide variety of therapeutics, including small molecules, macromolecules, and 
nanoparticles (6). The “Trojan-horse” approach of attaching therapeutic agents to ligands 
that bind a transyctosing receptor was proposed decades ago (5), and has been actively 
explored for TfR at the BBB (7,8). Despite several decades of investigation of Abs targeted 
to TfR (9-19), no viable clinical candidates have emerged. Two main limiting factors have 
hindered their successful translation to the clinic: (i) lysosomal sequestration of high-
  
107 
affinity anti-TfR Abs (14) and (ii) the need for very high systemic doses of lower-affinity 
variants to achieve sufficient brain accumulation (12). 
Using AuNPs as a model system, our group investigated whether TfR-targeted 
nanoparticles were similarly restricted at the BBB and found that brain uptake of high-
avidity AuNPs was limited in a similar way to high-affinity Abs (20). Follow-up work 
showed that high-avidity, TfR-targeted AuNPs could be made capable of accumulating in 
the brain in high numbers using acid-cleavable targeting ligands (21). Nanoparticles were 
chosen for their ability to be loaded with large quantities of drug that can be released at a 
tunable rate (22). The primary goal of this work was to determine whether therapeutic-
containing polymeric nanoparticles targeted to TfR using this methodology could be 
prepared to deliver a pharmacologically active amount of drug across the BBB/BTB. 
Initially focusing on drug delivery to HER2-positive breast cancer brain metastases, we 
addressed two important aspects of developing and translating new therapies. 
First, we addressed the pressing ‘mouse-to-human’ translational challenge facing 
the drug development community (23,24). We developed a new murine model of HER2-
positive breast cancer brain metastasis that involves IV injection of human breast cancer 
cells in an attempt to create a clinically representative, impermeable BBB/BTB to standard 
therapeutics. We compared this new model to two types of models from the literature that 
involve IC or ICD injection of the cancer cells, and demonstrated that the method – IC, 
ICD, or IV administration of HER2-positive breast cancer cells – used for creating brain 
metastases can have an impact not only on the evolution of the brain tumor, but also on its 
uptake of and response to therapeutics. Our results show that IC-formed brain tumors 
permit significant penetration of non-BBB-permeable therapeutics, whereas ICD- and IV-
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formed brain tumors maintain a more intact BBB/BTB. These findings suggest that the IC 
model must be used with caution for translational research where a non-permissive BBB 
is clinically relevant, particularly if the experimenter is interested in understanding 
therapeutic brain penetration (25). 
Second, we demonstrated a methodology for delivery of a small molecule drug 
across the BBB/BTB to breast cancer brain metastases in mice. We prepared TfR-targeted, 
single-agent therapeutic nanoparticles with acid-cleavable targeting ligands, and observed 
that treatment with these targeted nanoparticles led to a marked delay in tumor progression 
as well as high accumulation in brain tumors across all three murine models. Furthermore, 
TfR-targeted nanoparticles showed significant penetration in healthy brain tissue that 
resulted in whole-brain penetration, validating the therapeutic potential of the delivery 
system (25).  
In summary, this work details the development of a new mouse model of HER2-
positive breast cancer brain metastasis with high clinical relevance, enabling more 
meaningful translational studies of therapeutic brain penetration. It also presents the design, 
development and investigation of TfR-targeted, therapeutic nanoparticles capable of 
crossing the BBB/BTB using acid-cleavable targeting ligands. These TfR-targeted, 
polymeric nanoparticles can effectively deliver a small molecule therapeutic to the brain, 
and have tremendous potential in treating brain metastases as well as other brain diseases. 
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Appendix A 
DEVELOPMENT OF LAPATINIB-LOADED MUCIC                           
ACID POLYMER NANOPARTICLES FOR DELIVERY                            
TO BREAST CANCER BRAIN METASTASES 
A.1 Preamble 
The ultimate goal of our work is to develop targeted nanoparticles that are able to 
cross the BBB/BTB and effectively deliver combinations of therapeutic agents to 
intracranial cancers. As previously mentioned, we believe that TfR-targeted nanoparticles 
delivering therapeutic agents with greater potency may elicit a stronger antitumor response 
than was observed for the MAP-CPT nanoparticles. To this end, we investigated the 
incorporation of a more potent HER2-targeted small molecule agent, lapatinib, into the MAP 
polymer delivery system. As a targeted cancer therapy, lapatinib may enable more 
significant tumor knockdown, while maintaining a safer toxicity profile following whole-
brain distribution relative to a standard chemotherapeutic. The following is development 
work completed towards this objective, performed in parallel with the investigation of 
MAP nanoparticles as shuttles for macromolecular therapeutic agents detailed in Chapter 
III.   
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A.2 Introduction 
HER2-positive, metastatic breast cancer eventually becomes resistant to 
trastuzumab (1,2), and in some patients the cancer recurs after adjuvant therapy (3,4), often 
with the development of brain metastases (5-7). Poor penetration of HER2-targeted agents 
through the BBB and BTB limits improvement of clinical outcomes. For these reasons, 
there is a need for alternative treatment strategies to increase the brain uptake of 
therapeutics that block the HER2 signaling pathway.  
Lapatinib is an orally active small molecule that inhibits the tyrosine kinases of 
HER2 and epidermal growth factor receptor type 1 (EGFR) (8). Lapatinib was approved 
for use in combination with capecitabine by the FDA in 2007 for the treatment of 
metastatic, HER2-positive breast cancer that has progressed with standard treatment (9). 
The approval followed the results of a pivotal trial comparing combination lapatinib and 
capecitabine versus capecitabine alone in HER2-positive, metastatic breast cancer patients 
previously treated with anthracycline, taxane, and trastuzumab treatment (10,11). Patients 
in the combination group, when compared to those on capecitabine alone, showed an 
improvement in response rate and progression-free survival (PFS) by 4 months (8.4 vs. 4.4 
months) (10).  
In addition to combination with cytotoxic agents, there is interest in lapatinib 
combination therapy with trastuzumab for patients with advanced HER2-positive breast 
cancer. Dual targeting of HER2-positive breast cancer tumors with lapatinib and 
trastuzumab has garnered interest for several reasons, including their: (i) non-overlapping 
mechanisms of action, and (ii) potential synergistic effects, as demonstrated in preclinical 
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breast cancer models (12-14). In a clinical setting, trastuzumab inhibits ligand-independent 
HER2 signaling, but also induces apoptosis though antibody-dependent cellular 
cytotoxicity (ADCC) (15,16). In contrast, lapatinib inhibits ligand-dependent signaling and 
blocks downstream MAPK and PI3K signaling to prevent cell proliferation and survival 
(17). Additionally, lapatinib can induce accumulation of HER2 on the cell surface, 
potentiating trastuzumab-dependent ADCC (14). Furthermore, a clinical study comparing 
combination lapatinib and trastuzumab versus lapatinib alone in metastatic, HER2-positive 
breast cancer patients with trastuzumab-refractory disease showed improved PFS when 
compared to lapatinib alone (12.0 vs. 8.1 weeks) (18). 
Because of its low molecular weight and lipophilic nature, it has been suggested 
that, in contrast to trastuzumab, lapatinib may cross the BBB. However, a positron emission 
tomography (PET) study performed using carbon-11 radiolabeled lapatinib ([11C]lapatinib) 
showed a consistent lack of uptake in healthy brain tissue in patients with and without brain 
metastases (19). Furthermore, brain metastases in this PET study showed a modest, but 
highly variable uptake of [11C]lapatinib. These results are consistent with clinical data that 
showed a 60-fold variability in lapatinib uptake in brain metastases resected from patients 
after oral lapatinib treatment and preclinical studies in mice (20,21). Additionally, brain 
metastases at their earliest stages, where one may expect to have the greatest change of 
effective treatment, are hidden behind an intact BBB. By the time that these tumors grow 
to sufficient size to begin to demonstrate some partial BBB permeability (19,20), it likely 
may be too late to achieve effective therapy. 
The goal of this work was to prepare TfR-targeted, lapatinib-loaded nanoparticles 
for future use as a single-agent therapeutic or in combination with trastuzumab assembled 
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on the nanoparticle surface (Fig. A.1). Here, we synthesize two modified MAP polymer 
scaffolds that are used to prepare urea- and carbamate-based lapatinib polymer-drug 
conjugates that allow for the assembly of TfR-targeted, lapatinib-loaded nanoparticles. 
Ureas and carbamates are commonly used in medicinal chemistry, particularly in many 
prodrugs – chemically modified forms of a pharmacologically active agent that undergo in 
vivo modification to release the native drug molecule (22-24). The prodrug strategy helps 
to mitigate a number of challenges in achieving suitable physiochemical or 
pharmacokinetic drug properties, such as poor aqueous solubility, rapid clearance, and 
toxicity (25). Typically, release of the active drug molecule requires a triggering condition, 
such as a change in pH or presence of an enzyme. Most pharmacologically relevant urea 
and carbamate prodrugs have been designed as substrates of particular enzymes, including 
the previously mentioned small molecule capecitabine, a carbamate prodrug of 5-
fluororacil that requires three enzymes for conversion to the active drug (26,27). Whether 
these types of linkages can be used to release lapatinib under physiologic conditions in the 
brain remains to be determined. 
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Fig. A.1. Preparation of TfR-targeted, MAP*-lapatinib or combination lapatinib and 
trastuzumab nanoparticles. x ~ 82 for 3.4kDa PEG; y ~ 20 for material used in this study; z ~ 
120 for 5kDa PEG; w ~ 84 for 3.5 kDa PEG. MAP* denotes MAP derivative. 
A.3 Results and discussion 
A.3.1 Lapatinib displays increased in vitro cytotoxicity in HER2-positive 
BT474-Gluc cells when compared to CPT 
An in vitro cytotoxicity assay was performed using the HER2-positive BT474-Gluc 
human breast cancer cell line to determine the sensitivity of the tumor cells to lapatinib. 
Cells were incubated with media containing increasing concentrations of lapatinib or CPT. 
After 72 h of incubation, sensitivity of the BT474-Gluc cells to the small molecule agents 
was determined using a commonly used cell proliferation assay (28). Untreated cells were 
used as controls. 
Lapatinib showed significantly higher cytotoxicity against BT474-Gluc cells when 
compared to CPT, consistent with its greater expected potency (Fig. A.2). The IC50 value 
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for lapatinib was nearly 3-fold lower than that for CPT (ca. 120 µM and 45 µM, 
respectively). These data suggest that TfR-targeted MAP nanoparticle delivery of lapatinib 
to brain metastatic BT474-Gluc tumors may give rise to greater antitumor activity in vivo 
than was observed for CPT.  
 
Fig. A.2. Lapatinib shows greater cytotoxicity against BT474-Gluc cells relative to CPT. 
Data shown are the average of 4 dose-response curves for lapatinib (A) and CPT (B). Error 
bars indicate SE. 
A.3.2 Synthesis of MAP-amidoethanamine and MAP-amidoethanol polymer 
scaffolds for lapatinib conjugation 
A number of conjugation strategies can be applied to synthesize polymer-drug 
conjugates (Fig. A.3). However, the chemical linkage must allow lapatinib to release from 
the polymer backbone under extracellular conditions within the brain once the nanoparticle 
has transcytosed the BBB/BTB. For this reason, highly stable amides are not compatible 
for this application. Additionally, lapatinib has limited functional groups available for 
conjugation to the polymer, containing only secondary amines in its native state that can 
potentially be used to couple the drug to the MAP polymer (Fig. A.4). Thus, esters that 
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require the presence of a hydroxyl group – as was used in the synthesis of the MAP-CPT 
conjugate (1) – and imines that require the availability of a primary amine, were also ruled 
out. The most promising approaches remaining were the formation of either a urea or 
carbamate linkage between the secondary amine of lapatinib and the MAP polymer that is 
generally more susceptible to hydrolysis than amides (29). To achieve this, MAP needed 
to be modified to contain either a primary amine or hydroxyl functional handle, 
respectively (Fig. A.5). 
 
Fig. A.3. Common chemical linkages used in synthesis of conjugates. 
 
Fig. A.4. Structure of lapatinib. Lapatinib contains only secondary amine moieties 
(magenta) that can be used for conjugation to the polymer. 
 
Fig. A.5. Urea and carbamate formation between lapatinib and modified MAP polymer. 
Secondary amines on lapatinib can be used to form a urea (A) or carbamate (B) bond with 
MAP that is modified to contain accessible amine or hydroxyl moieties. MAP* and MAP† 
denote these MAP derivatives. 
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N-Boc-ethylenediamine was added to MAP, followed by acid deprotection to yield 
MAP-amidoethanamine (Fig A.6A). Similarly, in a separate synthesis, 2-(benzyloxy)-
ethan-1-amine was added to MAP, followed by deprotection using hydrogenation to yield 
MAP-amidoethanol (Fig. A.6B). Tert-butyloxycarbonyl (tert-Boc) and benzyl protecting 
groups were used to prevent crosslinking of the MAP polymer during the reaction. These 
modifications converted the carboxylic acid groups of MAP to amine or hydroxyl moieties 
to allow subsequent addition of lapatinib to the polymer through either a urea or carbamate 
bond, respectively. The MAP, N-Boc-ethylenediamine, 2-(benzyloxy)ethan-1-amine and 
intermediate reaction products leading to the preparation of MAP-amidoethanamine and 
MAP-amidoethanol were fully characterized by NMR (Fig. A.7 to A.13). The amine 
content in the MAP-amidoethanamine, as determined by a TNBSA assay, was 74%. 
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Fig. A.6. Synthesis of modified MAP polymer scaffolds to allow addition of lapatinib. (A) 
MAP-amidoethanamine. (B) MAP-amidoethanol. x ~ 82 for 3.4kDa PEG; y ~ 20 for 
material used in this study. 
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Fig. A.7. 1H NMR of unmodified MAP. Lowercase letters (a–i) shown above peaks 
correspond to chemical shifts of protons indicated on the chemical structure. 
 
Fig. A.8. 1H NMR of N-Boc-ethylenediamine. Lowercase letters (a–e) shown above peaks 
correspond to chemical shifts of protons indicated on the chemical structure. 
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Fig. A.9. 1H NMR of N-Boc-protected MAP-amidoethanamine. Peaks from amide adjacent to 
tert-Boc protecting group (b) and tert-Boc (c) are both present in the purified MAP-
amidoethanamine intermediate, along with an additional amide (a) peak and no unreacted amine. 
 
Fig. A.10. 1H NMR of MAP-amidoethanamine (black trace) compared that before 
deprotection (gray trace). Peaks from tert-Boc protecting group and adjacent amide are no 
longer present. 
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Fig. A.11. 1H NMR of 2-(benzyloxy)ethan-1-amine. Lowercase letters (a–e) shown above 
peaks correspond to chemical shifts of protons indicated on the chemical structure. 
 
Fig. A.12. 1H NMR of Bzl-protected MAP-amidoethanol. Aromatic (c) and alkane (b) 
peaks from benzyl protecting are both present in the purified MAP-amidoethanol 
intermediate, along with an additional amide (a) peak and no unreacted amine. 
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Fig. A.13. 1H NMR of MAP-amidoethanol (black trace) compared that before deprotection 
(gray trace). Peaks from benzyl protecting group are no longer present. 
A.3.3 Lapatinib forms single carbamate product under mild conjugation 
conditions 
Reactivity of the lapatinib secondary amines was first investigated before adding 
the molecule to the MAP derivatives. The reaction of lapatinib with N,N'-disuccinimidyl 
carbonate (DSC) in deuterated DMSO was monitored by ESI and NMR (Fig. A.14). DSC 
was chosen because it is the smallest homobifunctional NHS ester coupling agent 
commercially available. Furthermore, it is significantly more stable and less toxic than 
similar crosslinking reagents, such as carbonyl diimidazole or triphosgene. In nonaqueous 
environments, DSC can react with two amine groups to form a substituted urea derivative 
or can be used to conjugate a hydroxylic compound with an amine-containing compound 
to form a carbamate linkage. 
  
125 
 
Fig. A.14. Reaction of lapatinib with N,N'-disuccinimidyl carbonate to form lapatinib 
succinimidyl carbamate. The molecular masses of lapatinib and lapatinib succinimidyl 
carbamate are shown above the corresponding chemical structures. 
ESI analysis confirmed DSC reactivity with lapatinib. Within 4 h, most of the 
lapatinib was converted to lapatinib succinimidyl carbamate, as determined by the 
increased abundance of the mass spectrum peak at m/z of 722 (Fig. A.15). Interestingly, 
no higher m/z species were detected, suggesting that only one secondary amine is 
converted to a succinimidyl carbonate per lapatinib molecule. 
 
Fig. A.15. Lapatinib shows high reactivity of a single secondary amine with DSC. Relative 
intensities of mass spectrum peaks at m/z of 581 (magenta) and 722 (black) corresponding 
to lapatinib and lapatinib succinimidyl carbamate species, respectively, are provided for 
various timepoints. Full conversion was achieved within 8 h. 
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To determine whether a single carbamate product or a mixture was formed, the 
crude product was further analyzed by NMR. Integration of the crude product 1H NMR at 
12 h revealed that near full conversion was achieved using an equimolar ratio of 
lapatinib:DSC, consistent with the ESI results (Fig. A.16). 1H NMR of native lapatinib is 
provided in Fig. A.17 for comparison. Interestingly, several peak pairs were observed for 
protons in proximity to the newly formed amide, indicating either the presence of rotamers 
or the formation of two different products. Furthermore, the peak associated with the more 
sterically hindered lapatinib amine was present, while the peak corresponding to the 
secondary amine between the furan and methanesulfonyl moieties was lost, suggesting that 
a single carbamate product was formed between DSC and the less sterically hindered 
amine. Additionally, a 2D 1H NOESY experiment was performed on the crude product at 
12 h. Crosspeaks for all peak pairs in the 1D spectrum were present and in phase with 
diagonal response, indicating rotational conformations in slow exchange (NOE 
correlations would be negative) (Fig A.18). These data further suggest the formation of a 
single lapatinib succinimidyl carbonate product with cis/trans rotamers.  
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Fig. A.16. 1H NMR of crude product at 12 h. Lowercase letters (a–x) shown above peaks 
correspond to chemical shifts of protons indicated on the chemical structures. Peak from 
secondary amine between furan and methanesulfonyl moieties is no longer present, but 
peak from more hindered secondary amine (s) is present. Several peak pairs (s,g,e,d,b,c) in 
proximity to formed amide are observed. Magnified regions of 1H NMR of lapatinib (gray) 
and crude product (black) for peaks s and e are provided (inset). 
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Fig. A.17. 1H NMR of unreacted lapatinib. Lowercase letters (a–t) shown above peaks 
correspond to chemical shifts of protons indicated on the chemical structures. Peaks were 
identified by expected chemical shifts and addition of D2O to locate exchangeable amine 
protons. 
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Fig. A.18. 2D 1H NOESY of crude product at 12 h. Crosspeaks are present and in phase 
for all peak pairs in 1D 1H NMR (circled). Locations of protons showing cis/trans rotamers 
are highlighted on inset chemical structure (blue). 
A.3.4 Addition of lapatinib to MAP-amidoethanamine and MAP-amidoethanol 
polymers through urea and carbamate bonds 
After verifying that lapatinib could be conjugated through one of its secondary 
amines, lapatinib was activated with DSC, followed by conjugation of the drug to either 
MAP-amidoethanamine or MAP-amidoethanol (Fig. A.19A). This synthesis scheme was 
chosen over activation of the polymer derivatives with excess DSC, followed by addition 
of lapatinib (Fig. A.19B) because the latter resulted in higher than expected drug loading 
and material that did not form nanoparticles. This was likely due to DSC reacting with 
nucleophiles on the MAP backbone in addition to the intended primary amine and hydroxyl 
  
130 
handles on MAP-amidoethanamine and MAP-amidoethanol, respectively. Additionally, 
we added equimolar activated lapatinib to the polymer instead of excess drug to prevent 
overloading of the MAP derivatives and limit conjugation to the sterically favored primary 
amine and hydroxyl moieties. 
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Fig. A.19. Synthesis of MAP-lapatinib polymer-drug conjugates. Schemes for urea-based 
coupling are provided as an example. Carbamate-based analogs were prepared using MAP-
amidoethanol in place of MAP-amidoethanamine. (A) Activation of lapatinib with DSC, 
followed by addition of amidoethanamine derivative. (B) Activation of amidoethanamine 
derivative with DSC, followed by addition of lapatinib. 
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Following synthesis of the urea- and carbamate-based MAP-lapatinib conjugates, 
the quantity of lapatinib loaded onto the polymer was determined using absorbance 
detection and HPLC. The drug content for these conjugates was 11.2 and 10.7% (w/w 
lapatinib/MAP), respectively. These amounts are comparable to the drug loading achieved 
with CPT previously. 
A.3.5 Preparation and characterization of lapatinib-loaded, TfR-targeted 
MAP nanoparticles 
MAP-lapatinib conjugates were dialyzed against water to promote formation of 
nanoparticles with hydrophobic lapatinib molecules preferentially clustered in the core and 
vicinal diols on the surface. Both the urea and carbamate conjugate nanoparticle 
formulations had diameters near 50 nm without targeting agent, as measured by dynamic 
light scattering, and near-neutral zeta potentials when measured in pH 7.4 buffer (Table 
3.2). To prepare TfR-targeted MAP-lapatinib nanoparticles, Tf-PEG-nitroPBA was 
prepared as previously described (Chapter III) and added to the nanoparticles at 20 molar 
excess. Addition of the targeting agent led to a moderate decrease in nanoparticle size, 
consistent with steric stabilization provided by the Tf-PEG groups upon complexation with 
the nanoparticle core. These data suggest that the mucic acid groups are not modified 
during the conjugate synthesis. Thus, it appears that conjugation was limited to the more 
accessible primary amine and hydroxyl moieties by first activating lapatinib with DSC 
followed by its equimolar addition to the MAP derivatives. 
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Table A.1. Nanoparticle formulations and characteristics. MAP* and MAP† denote amine- 
and hydroxyl-containing MAP derivatives, respectively. Data shown for hydrodynamic 
diameter and zeta potential are the average of 5 measurements ±1 SD. 
A.4 Conclusions 
Here, we detail the synthesis of two modified MAP polymer scaffolds that contain 
primary amine and hydroxyl functional handles for drug conjugation. Urea- and carbamate-
based lapatinib polymer-drug conjugate materials were prepared with high drug loading. 
Nanoparticles formed by these conjugate materials retained the optimal design parameters 
identified in our previous investigations, including a sub-100-nm diameter and near-neutral 
zeta potential. Before use in a brain metastasis model, the drug release kinetics would need 
to me measured to determine whether the urea and carbamate linkages can be used to 
release lapatinib under physiologic conditions in the brain. If these nanoparticles are 
capable of releasing native lapatinib at an acceptable rate (t1/2 ~ days), they could 
potentially be more effective against HER2-positive breast cancer brain metastases 
compared to the MAP-CPT nanoparticles. 
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A.5 Materials and methods 
Cytotoxicity Assay. BT474-Gluc cells were seeded at a density of 3,000 cells/well in 96-
well plates. After 24 h, media was removed and replaced with fresh media containing 
different concentrations of lapatinib or CPT. After 72 h, BT474-Gluc cell viability was 
measured using the CellTiter 96 Aqueous One Solution cell proliferation assay (Promega) 
on an Infinite M200 microplate reader (Tecan), according to the manufacturer’s protocol. 
Synthesis of MAP-Amidoethanamine.  
Synthesis of N-Boc-Protected MAP-Amidoethanamine. Anhydrous dimethyl sulfoxide 
(10 mL) was added under argon to dissolve MAP (200 mg, 1 equiv) in a 25 mL round-
bottomed flask. To this was added EDC (111 mg, 5.3 equiv) and NHS (50 mg, 4 equiv) 
dissolved in anhydrous dimethyl sulfoxide (3 mL), followed by N-Boc-ethylenediamine 
(64 µL, 4 equiv) and anhydrous N,N-diisopropylethylamine (75 µL, 4 equiv) dried over 
molecular sieves. The reaction was stirred under argon at room temperature overnight. The 
solution was dialyzed against dimethyl sulfoxide 3 times and nanopure water 2 times using 
a 10 kDa MWCO Spectra/Por 7 membrane (Spectrum). The solution was dialyzed against 
dimethyl sulfoxide and nanopure water using a 10 kDa MWCO Spectra/Por 7 membrane 
(Spectrum), filtered through a 0.2 µm Supor membrane Acrodisc syringe filter (Pall), and 
lyophilized to yield N-Boc-protected MAP-amidoethanamine (182 mg) as a white, sponge-
like solid. 
Synthesis of MAP-Amidoethanamine. N-Boc-protected MAP-amidoethanamine (182 mg) 
in a 25 mL round-bottomed flask was placed in a water bath. 3 N hydrochloric acid in 
methanol (4 mL) was added, and the reaction flask was sealed and vented with a needle. 
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The reaction was stirred at 25 ºC for 8 h. Solvent was removed by rotary evaporation. The 
solid was dissolved in a 1:1 mixture of nanopure water and methanol (5 mL) and dried by 
rotary evaporation twice more. The solid was then reconstituted in nanopure water, 
dialyzed against water using a 10 kDa MWCO Spectra/Por 7 membrane (Spectrum), and 
then filtered through a 0.2 µm Supor membrane Acrodisc syringe filter (Pall) and 
lyophilized to yield MAP-amidoethanamine (160 mg) as a white, sponge-like solid. The 
product was stored under argon at -20 ºC. 
Determination of Amine Content in MAP-Amidoethanamine. Amine content was 
measured using the TNBSA Solution assay (5% (w/v), Thermo Scientific), according to 
the manufacturers protocol with the below modifications. MAP-amidoethanamine was 
prepared at 300, 200, and 100 µg/mL in reaction buffer. A standard curve of L-glutamic 
acid was prepared over a concentration range of 20 to 2 µg/mL in reaction buffer. 50 µL 
TNBSA working solution was added to 100 µL sample in a 96-well plate (Nunc) and 
briefly mixed. Absorbance at 355 nm was measured in triplicate on an Infinite M200 
microplate reader (Tecan) after 2 h incubation. 
Synthesis of MAP-Amidoethanol.  
Synthesis of Bzl-Protected MAP-Amidoethanol. Anhydrous dimethyl sulfoxide (10 mL) 
was added under argon to dissolve MAP (200 mg, 1 equiv) in a 25 mL round-bottomed 
flask. To this was added EDC (111 mg, 5.3 equiv) and NHS (50 mg, 4 equiv) dissolved in 
anhydrous dimethyl sulfoxide (3 mL), followed by 2-(benzyloxy)-ethan-1-amine (69 µL, 
4 equiv) and anhydrous N,N-diisopropylethylamine (75 µL, 4 equiv) dried over molecular 
sieves. The reaction was stirred under argon at room temperature overnight. The solution 
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was dialyzed against dimethyl sulfoxide 3 times and nanopure water 2 times using a 10 
kDa MWCO Spectra/Por 7 membrane (Spectrum). The solution was dialyzed against 
dimethyl sulfoxide and nanopure water using a 10 kDa MWCO Spectra/Por 7 membrane 
(Spectrum), filtered through a 0.2 µm Supor membrane Acrodisc syringe filter (Pall), and 
lyophilized to yield Bzl-protected MAP-amidoethanamine (194 mg) as a white, sponge-
like solid. 
Synthesis of MAP-Amidoethanol. Methanol (15 mL) was added to mucic acid Bzl-
protected MAP-amidoethanol (194 mg) and 20% (w) palladium hydroxide on carbon (200 
mg) in a 25 mL round-bottomed flask. The reaction flask was sealed and vented with argon 
for 30 min. Hydrogen gas was added by a double-layered balloon, and the reaction was 
stirred for 24 h at room temperature. Catalyst was separated by centrifugation at 3220 g for 
15 min, and the solvent removed by rotary evaporation. The solid was reconstituted in 
nanopure water, dialyzed against water using a 10 kDa MWCO Spectra/Por 7 membrane 
(Spectrum), and then filtered through a 0.2 µm Supor membrane Acrodisc syringe filter 
(Pall) and lyophilized to yield MAP-amidoethanol (179 mg) as a white, sponge-like solid. 
The product was stored under argon at -20 ºC. 
Synthesis of Lapatinib Succinimidyl Carbamate. Deuterated dimethyl sulfoxide (0.5 
mL) was added under argon to dissolve lapatinib (5 mg, 1 equiv, Sigma) in a 4 mL glass 
vial sealed with a septum. To this was added N,N'-disuccinimidyl carbonate (2.2 mg, 1 
equiv) dissolved in deuterated dimethyl sulfoxide (0.5 mL). The reaction was stirred under 
argon at room temperature. Aliquots were removed over time and assayed by ESI using a 
1:1 water:methanol solvent mixture. Electrospray ionization (ESI) masses of small 
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molecules were acquired on a Finnigan LCQ ion trap mass spectrometer. 1H NMR spectra 
were acquired on a Varian 600 MHz spectrometer (Inova) in deuterated dimethyl sulfoxide. 
Synthesis of MAP-Lapatinib Conjugates.  
Synthesis of Urea- and Carbamate-Based MAP-Lapatinib Conjugates. Anhydrous 
dimethyl sulfoxide (1 mL) was added under argon to dissolve lapatinib (7.6 mg, 1.2 equiv, 
Sigma) in a 10 mL round-bottomed flask. To this was added N,N'-disuccinimidyl carbonate 
(3.3 mg, 1.2 equiv) dissolved in anhydrous dimethyl sulfoxide (1 mL). The reaction was 
stirred under argon at room temperature for 6 h. MAP-amidoethanamine (20 mg, 1 equiv) 
was added to a separate oven-dried 10 mL round-bottomed flask. The flask was sealed, and 
vented with argon. To this was added anhydrous dimethyl sulfoxide (2 mL) to dissolve the 
polymer. The lapatinib solution was added dropwise to the polymer solution. The reaction 
was stirred under argon at room temperature overnight. The solution was dialyzed against 
dimethyl sulfoxide 3 times and nanopure water 2 times using a 10 kDa MWCO Spectra/Por 
7 membrane (Spectrum). Precipitate was removed by centrifugation at 3220 g for 15 min, 
and the supernatant was filtered through a 0.2 µm Supor membrane Acrodisc syringe filter 
(Pall) to yield MAP-lapatinib urea-based conjugate as self-assembled nanoparticles in 
solution. A portion of this clear yellow solution was lyophilized to determine percent 
lapatinib conjugation. The remaining product was formulated into 0.9% (w/v) saline and 
stored at -20 ºC. A similar procedure was followed using MAP-amidoethanol (20 mg, 1 
equiv) to synthesize MAP-lapatinib carbamate-based conjugate. 
Determination of Lapatinib Content in MAP-Lapatinib Conjugates. The amount of 
polymer-bound lapatinib was determined on an Agilent 1100 HPLC system with a reverse 
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phase column (Synergi 4 µm Hydro-RP 80 Å, Phenomenex) connected to a detector set to 
measure absorbance at 264 nm. 50% acetonitrile/50% potassium phosphate buffer (10 mM, 
pH 7.4) was used as the eluent at a flow rate of 0.5 mL/min. To cleave lapatinib from the 
polymer, 15 µL of 0.2 N NaOH was added to 20 µL sample and incubated for 3 h. Then, 
15 µL of 0.2 N HCl was added to neutralize the solution, followed by 30 min incubation. 
Subsequently, 150 µL methanol was added. The sample was centrifuged at 14000 g for 15 
min and supernatant filtered using a 0.45 µm PTFE membrane Millex-LH syringe filter 
(EMD Millipore). Lapatinib content was determined by injecting 100 µL of the filtered 
solution onto the column compared to a calibration curve of known concentrations of 
lapatinib. 
Synthesis of CO2H-PEG-nitroPBA.  
Synthesis of 3-acyl chloride-5-nitrophenyl boronic acid. 3-carboxy-5-nitrophenyl boronic 
acid (nitroPBA, 100 mg, 1 equiv, Alfa Aesar) was added to an oven-dried 10 mL round-
bottomed flask. The reaction flask was sealed and vented with argon. Anhydrous 
tetrahydrofuran with BHT inhibitor (4 mL) was added to dissolve the boronic acid, 
followed by anhydrous dimethylformamide (7 µL, 0.2 equiv). The flask was cooled to 0 
ºC in an ice bath, and oxalyl chloride (98 µL, 2.4 equiv) was added dropwise. After addition 
of oxalyl chloride, the ice bath was removed and the reaction was stirred under argon for 2 
hrs. Solvent was evaporated under vacuum to yield 3-acyl chloride-5-nitrophenyl boronic 
acid (97 mg) as a yellow solid. 
Synthesis of CO2H-PEG-nitroPBA. 3-acyl chloride-5-nitrophenyl boronic acid (46 mg, 2 
equiv) was added to an oven-dried 25 mL round-bottomed flask. The reaction flask was 
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sealed, vented with argon, and cooled to 0 ºC in an ice bath. Anhydrous DCM (5 mL) was 
added to dissolve the boronic acid. Acetic acid-PEG-amine (5 kDa, 500 mg, 1 equiv, 
JenKem) was added to a separate oven-dried 10 mL round-bottomed flask. The flask was 
sealed, and vented with argon. To this was added anhydrous N,N-diisopropylethylamine 
(35 µL, 2 equiv) dried over molecular sieves, and anhydrous DCM (5 mL) to dissolve the 
PEG. The PEG solution was added dropwise to the boronic acid solution. The reaction 
flask was left in the ice bath to slowly warm to room temperature, and stirred under argon 
overnight protected from light. Solvent was removed under vacuum, and the solid 
reconstituted in 0.5 N HCl (5 mL) and stirred for 15 min. The solution was filtered 0.2 µm 
Supor membrane Acrodisc syringe filter (Pall) and dialyzed against nanopure water until 
constant pH using a 15 mL Amicon Ultra 3 kDa spin filter (EMD Millipore), and 
lyophilized to yield CO2H-PEG-nitroPBA (436 mg) as a white solid.  
 
Synthesis of Tf-PEG-nitroPBA. CO2H-PEG-nitroPBA (8 mg, 25 equiv), EDC-HCl (3.1 
mg, 250 equiv), and NHS (2.8 mg, 375 equiv) were dissolved in 0.1 M MES buffer, pH 
6.0 (0.33 mL), and stirred for 15 min at room temperature. The reaction mixture was then 
added to a 0.5 mL Amicon Ultra 3 kDa spin filter (EMD Millipore), and centrifuged to 
isolate the activated nitroPBA-PEG-NHS ester. The ester was added to human holo-Tf (5 
mg, 1 equiv, Sigma) dissolved in 0.1 M PBS, 0.15 M NaCl, pH 7.4 (0.75 mL). The reaction 
was lightly agitated for 2 h at room temperature, and then dialyzed against 0.1 M PBS, 0.15 
M NaCl, pH 7.4 using 0.5 mL Amicon Ultra 50 kDa spin filters (EMD Millipore) to remove 
excess PEG. A portion of this solution was dialyzed into 10 mM PB, pH 7.4, and 
  
140 
conjugation was verified by MALDI-TOF (autoflex speed TOF/TOF, Bruker) using a 
sinapinic acid matrix. 
Preparation of Nanoparticles. Tf-PEG-nitroPBA conjugates in PBS, pH 7.4 were added 
at 20x molar excess to MAP-lapatinib nanoparticles to form TfR-targeted MAP-lapatinib 
nanoparticles (20 Tf per particle). The solution was gently mixed by pipette, and allowed 
to equilibrate for 10 min. Nanoparticle formulations were filtered using a 0.45 µm PTFE 
membrane Millex-LH syringe filter (EMD Millipore). 
Nanoparticle Characterization. Nanoparticles were characterized using a Brookhaven 
Instruments Corporation (BIC) ZetaPALS. Nanoparticles were diluted in PBS, pH 7.4 and 
hydrodynamic diameter was measured by dynamic light scattering (DLS) using BIC 
Particle Sizing Software. Particle formulations were diluted in 10 mM PB, pH 7.4 and zeta 
potential was measured using BIC PALS Zeta Potential Analyzer software with a target 
residual of 0.02. Five runs were performed for both the nanoparticle diameter and zeta 
potential measurements. 
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Appendix B 
NCI CANCER CLOSE UP 
B.1 Preamble 
 During my thesis work, I participated in the NCI Cancer Close Up project, an 
annual competition that gathers, shares, and exhibits visually compelling images (e.g., 
microscopy, in vivo, in vitro, etc.) that help illustrate the cancer research story. Because the 
focus of the 2017 NCI Cancer Close Up project was nanotechnology, I submitted two 
images from my NCI-supported research. One of the submissions, titled ‘Nanoparticles in 
Brain Metastases’, was selected and featured in NCI’s public image galleries (NCI Visuals 
Online and Instagram), shared via NCI’s Twitter and Facebook channels, as well as 
displayed on Cancer.gov. The submission was also selected as part of a smaller collection 
and prominently displayed at the NCI Exhibits at the 2017 AACR and ASCO annual 
meetings. The second submission was selected for the general image collection on NCI 
Visuals Online, titled ‘The Blood-Brain Barrier’. The following are the images selected by 
the reviewers.  
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B.2 Image selected for 2017 NCI Cancer Close Up 
 
Fig. B.1. Nanoparticles in brain metastases. Cancer that has spread (metastasized) to the 
brain is normally untreatable because the protective blood-brain barrier blocks entry of 
most therapeutics. Nanoparticles capable of carrying drugs and "hitchhiking" across the 
barrier may allow the delivery of life-saving therapies to these tumors. This image shows 
blood vessels (red), cell nuclei (blue), and human metastatic breast cancer cells (green) in 
a mouse's brain, after intravenous administration of experimental nanoparticles that can 
cross the blood-brain barrier. 
 
Link: https://visualsonline.cancer.gov/details.cfm?imageid=11170 
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B.3 Image selected for NCI Visuals Online 
 
Fig. B.2. The blood-brain barrier. This image shows a dense network of blood vessels (red) 
and nuclei (blue) obtained from mouse brain tissue that was optically cleared to look deeper 
into the tissue than otherwise possible. The brain’s blood vessels are nearly impermeable, 
allowing only the passage of key nutrients while blocking that of harmful substances. 
Unfortunately, this blood-brain barrier (BBB) also excludes most therapeutics. By 
designing drug-containing nanoparticles that can “hitchhike” across the BBB, researchers 
hope to finally penetrate the barrier, and deliver life-saving drugs to cancers in the brain.  
 
Link: https://visualsonline.cancer.gov/details.cfm?imageid=11169 
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B.4 Materials and methods 
IC Brain Metastasis Model. All animals were treated according to the NIH guidelines for 
animal care and use as approved by the Caltech Institutional Animal Care and Use 
Committee (1). BT474-Gluc cells, transduced with an expression cassette encoding Gluc 
and CFP separated by an internal ribosomal entry site using a lentiviral vector, were 
obtained from Dr. Jain at Harvard University. BT474-Gluc cells were maintained in RPMI 
1640 supplemented with 10% (v/v) FBS in a humidified oven at 37°C with 5% CO2. 50,000 
BT474-Gluc cells in 2 µL RPMI were intracranially injected into the right cerebral 
hemisphere of female Rag2-/-;Il2rg-/- mice (Jackson Laboratory) using a stereotaxic 
apparatus at a rate of 0.1 µL/min. The coordinates for injection were 2 mm posterior, 1.5 
mm lateral to bregma, and 2.5 mm depth from bregma.  
Tissue Processing. Mice were sacrificed following signs of prolonged distress or loss of 
>20% body weight. The mice were anaesthetized and transcardially perfused with a 10% 
sucrose solution, followed by a 4% (v/v) formaldehyde in PBS, pH 7.4. Excised brain tissue 
was post-fixed in 4% (v/v) formaldehyde in PBS, pH 7.4 overnight at 4 °C, then washed 
in PBS, pH 7.4 with 0.02% NaN3 to remove excess fixative. 1 mm-thick tissue sections of 
brain tumor and healthy brain tissue were prepared using the CLARITY method for 
clearing large tissue volumes (2). In short, tumor and healthy brain tissue were sectioned 
on a vibratome to a thickness of 1 mm, and stored at 4 °C, protected from light until further 
processing. Tissues were incubated in A4P0 hydrogel monomer solution (4% acrylamide 
in PBS, pH 7.4) overnight with shaking (acrylamide solution, Bio-Rad; thermal initiator, 
Wako). Samples were degassed, then polymerized in a 37 °C incubator for 3 h. Following 
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polymerization, samples were washed in PBS, pH 7.4 to remove residual hydrogel, then 
cleared at 37 °C with gentle agitation in 8% (w/v) SDS with 0.02% NaN3 in PBS, pH 8.0 
until optically transparent. Clearing times varied for tissue types. Samples were washed in 
PBS, pH 7.4 with 0.02% NaN3 for 2 days with minimum of four exchanges.  
For vasculature identification, brain samples were incubated with a 1:200 dilution of an 
anti-CD31 rabbit primary Ab (Abcam ab28364) and a 1:200 dilution of an AlexaFlor 594-
conjugated anti-rabbit donkey secondary Ab (Jackson ImmunoResearch 711-585-152) 
with 0.02% NaN3 in PBST for 7 days each with shaking to visualize vasculature. A 1:1000 
dilution of Draq5 (Cell Signaling) nuclear stain was added to secondary Ab cocktail. 
Immunostains were replaced every one-two days with fresh cocktail, and tissues were 
washed for two days with a minimum of four exchanges in PBST with 0.02% NaN3 
between stains and after final stain. Samples were incubated in RIMS (prepared with 
Histodenz, Sigma-Aldrich, RI = 1.46) with gentle agitation for one day. Glass slides were 
prepared with 1 mm iSpacers (SunJin Lab Co.). Samples were placed inside the spacer, 
followed by slight overfill of fresh RIMS, and a coverslip.  
Imaging. Z-stacks were acquired with a Zeiss LSM 710 confocal microscope using an 
Achroplan 20 / 0.5 NA water objective with ~40-50% overlap. Linear laser power z-
correction was applied in Zen software (Zeiss) to ensure uniform signal intensity 
throughout the sample, as even cleared tissue will scatter at depth. For comparative analysis 
between samples, all laser and gain settings were set at the beginning of imaging and were 
unchanged. Image analysis was performed with Imaris (Bitplane). 
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